Contents lists available at ScienceDirect



Diabetes & Metabolic Syndrome: Clinical Research & Reviews



Effects of testosterone therapy in adult males with hypogonadism and T2DM: A meta-analysis and systematic review



癯

Satesh Kumar ^{a, *}, Mahima Khatri ^b, Rahat Ahmed Memon ^c, Jordan Llerena Velastegui ^d, Kristina Zumbana Podaneva ^d, Daniela Benitez Gutierrez ^e, Bilawal Nadeem ^f, Akhil Raj Anumolu ^g, Masood Azhar ^h, Ahmad Zain ⁱ

^a Medicine, Shaheed Mohtarma Benazir Bhutto Medical College, Lyari, Parsa Citi Block E Flat 501 Near Police Headquarter, Garden East, Karachi, Pakistan

^b Medicine, Dow University of Health Sciences, Karachi, Karachi, Pakistan

^c Cardiology, Abington Jefferson Hospital, Pennsylvania, Pennsylvania, United States

^d Medicine, Pontifical Catholic University of Ecuador, Quito, Ecuador

e Medicine, International University of Ecuador, Quito, Ecuador

^f Medicine, Kind Edward Medical University, Lahore, Lahore, Pakistan

^g Medicine, Andhra Medical College, Visakhapatnam, Andhra Pradesh, India

^h Medicine, King Edward Medical University, Lahore, Lahore, Pakistan

¹ Medicine, Services Institute of Medical Sciences, Lahore, Lahore, Pakistan

ARTICLE INFO

Article history: Received 4 June 2022 Received in revised form 21 July 2022 Accepted 23 July 2022

Keywords: Hypogonadism testosterone replacement therapy TRT TST T2DM Type 2 diabetes mellitus meta-Analysis

ABSTRACT

Background and aims: Testosterone supplementation therapy (TST) is a longstanding treatment for hypogonadal men with type 2 diabetes mellitus (T2DM), even though the benefits of TST are variable among trials. This meta-analysis was done to determine the specific role of TST in hypogonadal men with T2DM.

Methods: PubMed, Embase, and Google Scholar were queried to discover eligible randomized controlled trials (RCTs) and observational studies. To quantify the specific effects of TST, we estimated pooled mean differences (MDs) and relative risks with 95% confidence intervals (CIs).

Results: Our meta-analysis included 1596 hypogonadal T2DM subjects from 12 randomized controlled trials and one observational study. TST can significantly enhance glycemic control compared to placebo by decreasing homeostatic model assessment of insulin resistance (WMD = -1.55 [-2.65, -0.45]; p = 0.26; I2 = 20.2%), fasting glucose (WMD = -0.35 [-0.79, 0.10]; p = 0.07; I2 = 69.7%), fasting insulin (WMD = -2.88 [-6.12, 0.36]; p = In addition, TST can decrease cholesterol (WMD = -0.28 [-0.47, -0.09] p = 0.0008; I2 = 91%) and triglyceride (WMD = -0.23 [-0.43, -0.03] p = 0.03; I2 = 79.2%). Furthermore, Testosterone therapy is related to a significant rise in total testosterone levels (WMD = 5.08 [2.90, 7.26] p = 0.0002; I2 = 92.9%). Pooling of free testosterone levels indicated a larger increase in the patients who got TST than placebo (WMD = 81.21 [23.87, 138.54] p = 0.07; I2 = 70%).

Conclusion: Our findings suggested that TST can enhance glycemic control and hormone levels and reduce total cholesterol, triglyceride, LDL cholesterol whereas increase HDL cholesterol in hypogonadal T2DM patients. Therefore, in these patients, we propose TST alongside anti-diabetic treatment.

© 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved.

1. Introduction

* Corresponding author.

https://doi.org/10.1016/j.dsx.2022.102588 1871-4021/© 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved. According to the 2018 Endocrine Society Clinical Practice Guidelines, hypogonadism is a clinical syndrome caused by the testis's inability to produce physiological testosterone levels or a normal percentage of spermatozoa due to pathology in one or more hormonal concentrations of the hypothalamic-pituitary-testicular axis [1]. The prevalence of hypogonadism in the general population ranges from 5 to 12.3% in men aged 30 to 79, with an incidence

E-mail addresses: kewlanisatish@gmail.com (S. Kumar), mahimakhatri12333@ gmail.com (M. Khatri), Rahatahmed227@yahoo.com (R.A. Memon), jordanllerena1994@gmail.com (J.L. Velastegui), zpodanevak@gmail.com (K.Z. Podaneva), dabenitezgu@gmail.com (D.B. Gutierrez), bilawal.ranjha@gmail. com (B. Nadeem), akhilrajanumolu@yahoo.com (A.R. Anumolu), masood_azhar@ hotmail.com (M. Azhar), ahmadzain99@gmail.com (A. Zain).

of 12.3 per 1000 inhabitants/year.2 Male hypogonadism is diagnosed when patients exhibit symptoms and signs of testosterone deficiency and consistently low serum total testosterone and free testosterone concentrations [1]. Free testosterone concentrations less than 225 pmol/l (65 pg/ml) are considered diagnostic and support the use of replacement therapy [2]. Hypogonadism can significantly impact patients' multiple organ functions and quality of life and has developed into a global medical issue. Numerous studies have recently established a link between type 2 diabetes mellitus (T2DM) and hypogonadism. This is because obesity is a strong risk factor for testosterone deficiency (TD), which further increases fat accumulation, insulin resistance (IR), and glycemic control deterioration, constructing a negative spiral [3]. Around 25%-33% of men with T2DM have hypogonadotropic hypogonadism, which has been implicated as a risk factor for developing T2DM. There is a growing and sometimes contradictory body of research examining whether testosterone should be used in the standard clinical management of T2DM [4].

Numerous studies have demonstrated that testosterone therapy improves metabolic syndrome (MetS) components, lipid profile, decreases fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) levels, improves insulin sensitivity, reduces inflammation, and decreases systolic as well as diastolic blood pressures in males with T2DM [5]. Additionally, long-term testosterone therapy has been proposed to prevent prediabetes progression to T2DM in men with hypogonadism and improve the quality of life as measured by the Aging Males' Symptoms (AMS) questionnaire [5]. Nevertheless, some studies produced contradictory findings. For example, several studies have shown that testosterone replacement therapy (TRT) can significantly reduce the homeostatic model assessment of insulin resistance (HOMA-IR) levels, fasting serum glucose (FSG), fasting serum insulin (FSI), and HBA1C percentage in hypogonadal patients with T2DM [6]. Moreover, other data indicated that these indicators did not decrease significantly in TRT groups. TRT has been associated with improvements in lipid panel variables such as total cholesterol (TC), triglycerides (TG), and serum low-density lipoprotein (LDL) cholesterol, as well as an increase in serum high-density lipoprotein (HDL) cholesterol in some studies [7,8]. Other studies failed to demonstrate a statistically significant improvement in lipid metabolism.

Meta-analysis is a research method used to systematically synthesize or merge the findings of single, independent studies, using statistical methods to calculate an overall or absolute effect, and test how sensitive their results are to their own systematic review protocol (study selection and statistical analysis). Only a few randomized control trials and observational studies have been conducted to investigate the role of TRT in male hypogonadism associated with TDM, and the majority of them have produced inconsistent findings. As a result, we conducted a systematic review and meta-analysis to ascertain the exact role of TRT in hypogonadal men with T2DM. To the best of our knowledge, this is the first recently updated meta-analysis that compares the various effects of testosterone therapy versus the control arm having placebo or no treatment.

2. Materials and methods

This meta-analysis was carried out in accordance with the Preferred Reporting Items for Systemic Review and Meta-Analysis (PRISMA) [9].

2.1. Search strategy

A thorough search was conducted on PubMed (Medline) and Cochrane from the study's beginning until the 5th of May 2022. Grey literature and preprints were identified by searching Clinical Trials. gov, Google Scholar, and Medrxiv. Utilizing Medical Subject Headings (MESH terms) and keywords, a search strategy was developed that contained ['Testosterone' OR 'TST' OR Testosterone undecanoate] AND ['Hypogonadism' OR 'Hormonal deficit'] AND [Diabetes Mellitus']. The search approach is specified in Table S1. The search results were not filtered or restricted in any way. Using Google's translate function, non-English language text was translated. Manual searches of review articles extracted relevant studies. Titles, complete texts, and abstracts of papers were separately examined by two reviewers (MK and SK). Relevant studies were imported into Endnote X9 (Clarivate Analytics, US) to eliminate duplications.

2.2. Eligibility criteria

2.2.1. Inclusion criteria

Studies included were selected based on the following: language, study design, patient population, intervention, comparison, outcomes of interest, and definition.

- English publications;
- Study design: Eligible completed randomized clinical trials or observational studies were extracted to perform the meta-analysis.
- Patient population: patients with confirmed type 2 diabetes who met the criteria of hypogonadism.
- Exposure: Patients who received testosterone therapy.
- Comparison: This includes the non-TST group, which received the usual standard of care or placebo.
- Outcomes of interest: effects on glucose metabolism, cholesterol levels, BMI, waist circumference, body fat, systolic and diastolic blood pressure, and post-treatment hormonal levels.

2.2.2. Exclusion criteria

To preserve the quality of this meta-analysis, the following significant exclusion criteria were outlined:

- No clear definitions of the diagnosis of late-onset hypogonadism and T2DM, population, amount and serving method of testos-terone, or outcome assessment
- No placebo or treatment groups
- Insufficient data for estimating a mean difference (MD) with a 95% confidence interval (CI)
- Duplicates of previous publications

In addition, all included RCTs were evaluated based on the 25item CONSORT checklists, which emphasize describing how the trials were conceived, analysed, and interpreted (Table S2). The quality of the included RCTs was evaluated based on the number of the 25 items that were reported. A correlation exists between the number of reported items and the quality of an RCT. High-quality research will report all 25 criteria.

2.3. Data Extraction

Two researchers (MK and SK) independently assessed the selected studies to determine whether a particular article should be included. A dialogue examined and resolved uncertain data. The following essential variables were retrieved from each study: first author's name, publication year, country, ethnicity, testosterone cut-off point, diabetes duration, testosterone regimen, drugs on comparators, mean age, Hba1c percentage, and total serum testosterone level. Table 1 details the previously mentioned data. Homeostatic model assessment of insulin resistance (HOMA-IR),

Table 1

Baseline characteristics of included studies.

Study	Study design	of	Hypogonadism cut off point	No pati	of ients	Age (Mean ±	SD)	Waist circum (Mean \pm SD)	ference (cm)	BMI (kg/m2)	$(Mean \pm SD)$
		patients		TRT	Placebo	TRT	Placebo	TRT	Placebo	TRT	Placebo
Dhindsa (2015) [13]	RCT	34	FT < 225 pmmol/L	20	14	$\textbf{54.6} \pm \textbf{7.9}$	54.6 ± 7.9	128 ± 20	124 ± 30	39.0 ± 7.6	39.4 ± 7.9
Gianatti (2014) [8]	RCT	67	TT < 12 nmmol/L	37	30	62 ± 2.5	62 ± 2.5	110 ± 4.2	115 ± 2.75		
(2014) [14]	RCT	186	TT < 12 nmmol/L	91	95	61.2 ± 10.5	62.0 ± 9.3	115.1 ± 13.1	112.6 ± 13.3	33.0 ± 6.1	32.4 ± 5.5
Jones (2011) [15]	RCT	137	TT < 11 nmmol/L	68	69	59.9 ± 9.1	59.9 ± 9.4	112.7 ± 13.35	111.7 ± 15.23	32.76 ± 6.12	31.56 ± 5.87
Gopal (2010) [16]	RCT crossover	22	FT < 225 pmmol/L	22	22	44.23 ± 3.29	44.23 ± 3.29	93.25 ± 7.03	84.10 ± 13.86	25.44 ± 3.57	22.10 ± 4.93
Heufelder (2009) [17]	RCT	32	TT < 11 nmmol/L	16	16	57.3 ± 1.4	55.9 ± 1.5	107.9 ± 1.3	105.7 ± 1.4	32.1 ± 0.5	32.5 ± 0.6
Kapoor (2006) [18]	RCT crossover	27	TT < 12 nmmol/L	24	24	64 ± 1.34	64 ± 1.34	115.1 ± 2.4	115.1 ± 2.4	33 ± 0.86	33 ± 0.96
Boyanov (2003) [19]	RCT	48	TT < 15 nmmol/	24	24	57.5 ± 4.8	57.5 ± 4.8	N/A	N/A	31.08 ± 4.79	31.01 ± 4.90
Hackett (2018) [20]	RCT	537	TT < 12 nmmol/L	175	i 362	58.3 ± 11	65.5 ± 11.8	N/A	N/A	32.6 ± 6.4	31.7 ± 5.9
Yassin (2019) [12]	Observational study	316	TT < 12.1 nmol/L	229	87	58.2 ± 9.6	66.4 ± 7.2	104.2 ± 7	101.1 ± 9.9	30.7 ± 4.1	29.8 ± 3
Khirpun (2018) [21]	RCT	80	serum levels of total testosterone two times below 12.1 nmol/L or serum levels of free testosterone two times below 243 pmol/L in combination of at least two symptoms or complaints of sexual or psychological nature		40	53.3 ± 5.4	54.1 ± 5.6	114.3 ± 9.5	114.7 ± 9.8	34.0 ± 2.6	33.6 ± 2.9
Groti (2020) [5]	RCT	55	(total testosterone [TT] below 11 nmol/L and free testosterone below 220 pmol/L) on at least two separate morning measurements after an overnight fast in addition to exhibiting at least two symptoms of sexual dysfunction (less frequent morning e	28	27	58.21 ± 7.94	62.19 ± 5.90	116.48 ± 5.07	115 ± 1.47	34.03 ± 4.37	32.63 ± 3.67
Groti (2018) [22]	RCT	55	total testosterone (TT) level <11 nmol/l and/or free testosterone (FT) level <220 pmol/l	28	27	N/A	N/A	116.48 ± 5.07	116.64 ± 4.96	34.03 ± 4.37	32.63 ± 3.67

SD: Standard deviation, Ft: free testosterone, TT: total testosterone.

fasting plasma glucose (FSG), fasting serum insulin (FSI), HbA1c, total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholestreol, body fat, BMI index, systolic and diastolic blood pressure (SBP and DBP), Aging male score (AMS) and international (IIEF).

2.4. Study quality assessment

The modified Cochrane Collaboration's risk of bias tool was used to assess the quality of published RCTs [10], observational studies were assessed using New Castle Ottawa scale [11].

2.5. Statistical analysis

Review Manager 5.4 (Cochrane Collaboration) software was used to conduct the proposed meta-analysis. Relative risks (RRs) and their respective 95% confidence intervals (CI) were retrieved for dichotomous outcomes. Continuous outcomes were given with mean values and standard deviations. This meta-analysis presents a pooled effect of relative risks (RRs) and weighted mean differences (WMDs) calculated using the generic-inverse variance and continuous outcome functions with a random-effects model. All p values less than 0.05 were deemed statistically significant. Funnel plots for all outcomes were visualized to assess publication bias.

Using I2 statistics, heterogeneity between trials was measured and reported as a percentage. Low heterogeneity was indicated by an I2 value of 25%, moderate heterogeneity between 25% and 50%, and high heterogeneity by an I2 value above 50%. Results from studies with a significant proportion of heterogeneity were subjected to sensitivity analysis to determine how each study affected the pooled estimate.

Table 2
Baseline glucometabolic, lipid and blood pressure parameters.

Study	Fasting plass (mmol/L) (N	0	Fasting serum (Mean ± SD)	insulin	HbA1c %		Free testostero	ne (Mean ± SD)	Total testos (Mean ± SI		HOMA-IR (M	Mean ± SD)	Mean total (Mean ± SE		Systolic blood (Mean ± SD)	pressure	Diastolic blo (Mean ± SD)	•
Dhindsa (2015) [13]	TRT 6.99 ± 0.44		TRT 13.6 ± 3	Placebo 11.8 <u>+</u> 2.2	TRT 6.8 ± 0.9	Placebo 7 ± 1.4	TRT 156.5 ± 45.11	Placebo 145.74 ± 41.6	TRT 9 ± 2.9	Placebo 8.3 ± 2.8	TRT 9 ± 2.9	Placebo 8.3 <u>+</u> 2.8	TRT 4.06 ± 0.98	Placebo 5 4.03 ± 0.95	TRT	Placebo	TRT	Placebo
Gianatti (2014) [8]	9.57 ± 3.78	9.11 ± 3.65	N/A	N/A	7.7 ± 1.3	7.5 ± 1.2	187.7 ± 57.0	181.2 ± 63.6	9.2 ± 3.1	8.9 ± 3.8	4.1 ± 2.0	3.7 ± 2.6	4.15 ± 0.90	4.08 ± 0.9	140.2 ± 15.9	137.1 ± 13.0	79.4 ± 9.4	77.5 ± 8.9
		8.49 ± 2.84	20.88 ± 22.83	18.17 ± 15.7	N/A	N/A	198 ± 49.3	202.4 ± 62.1	9.2 ± 2.6	9.5 ± 3.3	5.9 ± 3.8	4.9 ± 3.3	4.51 ± 1.17	4.55 ± 1.01	138.6 ± 17.30	136.7 ± 17.12	82.5 ± 10.23	81.6 ± 9.50
	7.9 ± 4.3	9.2 ± 3.4	12.80 ± 8.95	17.86 ± 24.72	6.43 ± 2.20	7.69 ± 2.77	177.57 ± 60.19	177.57 ± 60.19	0 10.1 ± 3.7	10.1 ± 3.7	5.50 ± 6.82	6.45 ± 8.75	4.7 ± 0.9	4.0 ± 1.0	115.83 ± 5.15	118.40 ± 9.97	82.00 ± 6.93	79.00 ± 3.1
Gopal (2010)	7.9 ± 0.2	8.3 ± 0.2	19.03 ± 0.63	16.8 ± 0.87	7.5 ± 0.1	7.5 ± 0.1	200 ± 0.00	200 ± 0.00	10.5 ± 0.2	10.4 ± 0.2	5.6 ± 0.3	6.1 ± 0.4	N/A	N/A	104.5 ± 2.6	143.5 ± 2.1	85.6 ± 0.9	85.0 ± 1.0
	7.83 ± 0.49	7.6 ± 0.43	13.68 ± 1.95	12.37 ± 1.87	7.28 ± 0.19	0 7.28 ± 0.19	N/A	N/A	8.63 ± 0.51	8.63 ± 0.51	1 N/A	N/A	5.11 ± 0.17	4.95 ± 0.15	127.6 ± 2.8	131 ± 3.1	74 ± 1.4	74 ± 1.4
(2006)	8.0 ± 2.6	8.4 ± 2.8	N/A	N/A	10.4 ± 1.6	10.3 ± 1.6	N/A	N/A	9.56 ± 2.33	3 10.76 ± 3.0	D N/A	N/A	5.50 ± 1.41	5.59 ± 1.49	122 ± 8	120 ± 8	80 ± 4	76 ± 6
[10] Boyanov (2003) [19]	N/A	N/A	N/A	N/A	7.6 ± 1.3	7.5 ± 1.5	210 ± 124.5	175 ± 67.9	9.7 ± 4.4	8.9 ± 3.2	N/A	N/A	4.5 ± 1.1	4.1 ± 1.0	141.8 ± 16.1	139.4 ± 16.8	81.4 ± 10.4	78.2 ± 10.4
(2018)	5.3 ± 0.8	4.9 ± 1.3	N/A	N/A	5.9 ± 0.2	5.9 ± 0.2	N/A	N/A	8.2 ± 2.1	9.6 ± 2.4	N/A	N/A	6.9 ± 1.2	6.4 ± 1.4	136.9 ± 13.5	129.8 ± 12.7	81.2 ± 8.9	84.7 ± 6.7
Yassin (2019)	8.1 ± 3.7	8.7 ± 5.0	N/A	N/A	7.8 ± 2.4	7.9 ± 2.4	208 ± 142	223 ± 140	9.6 ± 2.7	9.9 ± 2.6	N/A	N/A	6.1 ± 1.2	5.9 ± 1.5	N/A	N/A	N/A	N/A
Khirpun (2018) [21]	10.06 ± 1.44	9.77 ± 1.40	N/A	N/A	8.12 ± 1.04	1 7.89 ± 0.77	208 ± 142	223 ± 140	7.24 ± 1.97	7.96 ± 1.34	4 11.45 ± 7.34	4 10.82 ± 6.52	5.31 ± 0.91	5.11 ± 0.85	134.64 ± 10.71	138.15 ± 13.24	4 77.50 ± 5.85	78.89 ± 5.2
	10.06 ± 1.44	9.60 ± 1.44	26.03 ± 15.86	24.89 ± 13.90	8.12 ± 1.04	1 7.89 ± 0.77	N/A	N/A	7.24 ± 1.97	7.96 ± 1.34	4 11.45 ± 7.34	4 10.70 ± 6.52	5.31 ± 0.91	5.31 ± 0.97	134.64 ± 10.71	138.15 ± 13.24	4 77.50 ± 5.85	78.89 ± 5.2
Groti (2018) [22]	10.06 ± 1.44	9.60 ± 1.44	26.03 ± 15.86	24.89 ± 13.90	8.12 ± 1.04	1 7.89 ± 0.77	N/A	N/A	7.24 ± 1.97	7.96 ± 1.34	4 11.45 ± 7.34	4 10.70 ± 6.52	5.31 ± 0.91	5.31 ± 0.97	134.64 ± 10.71	138.15 ± 13.24	4 77.50 ± 5.85	78.89 ± 5.2

SD: Standard deviation, HOMA-IR: Homeostasis model of insulin resistance, HbA1c: glycated hemoglobin.




Fig. 1. Prisma flow chart.

3. Results

3.1. Study selection

A total of 247 articles were identified from the preliminary literature search. After eliminating duplicated articles and based on title and abstract, a total of 13 studies (1 observational [12] and 12 RCTs [5,8,13–22]) were included in this meta-analysis. Characteristics of included studies are reported in (Supplementary Tables S2 and S3)

3.2. Baseline characteristics

Totalling 1596 participants, the 13 studies included people who met the clinical definition of hypogonadism, with 802 receiving testosterone and 837 receiving a placebo. At least three sexual symptoms and total testosterone (TT) or TT12 nmol/L were considered hypogonadism in five studies [8,12,14,18,20], while TT15 nmol/L or free testosterone (FT) 225 pmol/L was defined as hypogonadism in other studies [5,13,15-17,19,21,22]. The primary testosterone regimen varied among the studies that were enrolled. One [19], three [15,17,21], and nine [5,8,12-14,16,18-20,22] studies respectively used oral testosterone, testosterone gel by intradermal injection, and testosterone by deep intramuscular injection. There were a variety of dosages and timings for testosterone use in these investigations. Double-blind placebo-controlled studies accounted for ten [5.8.13–16.18.20–22] of the 12 RCTs, whereas the other two [17,19] was conducted with no control group. As indicated by the research type, Tables 1 and 2 provides information on participants' baseline characteristics, medical conditions, hormone levels, and glycaemic indices.

3.3. Quality assessment and publication bias

Using the New Castle Ottawa scale to assess the quality of studies, it was determined that the observational study had a low risk of bias (Supplementary Table 4). The Cochrane method of

evaluating RCTs indicated trials of fair to good quality (Supplementary Table 5). The funnel plots demonstrated that the quantitative results were not affected by publication bias (Supplementary Fig. S1) (see Fig. 1).

3.4. The effects on glucometabolism (Fig. 2)

The effects of testosterone on glucometabolism were evaluated using the variables HOMA-IR, HbA1c, fasting serum glucose (FSG), and fasting serum insulin (FSI). The data on HOMA-IR was reported by 8 [5,8,13,14,16,17,21,22] out of 13 studies and revealed that therapy with testosterone lowered HOMA-IR levels to a greater level than placebo (WMD = -1.55 [-2.65, -0.45]; p = 0.26; I2 = 20.2%). Similarly, 12 [5,8,12–19,21,22] out of 13 studies recorded FSG, and patients in the testosterone group showed a higher reduction in FSG following treatment than those in the placebo group (WMD = -0.35[-0.79, 0.10]; p = 0.07; l2 = 69.7%). Seven [8,13,15-18,22] out of thirteen studies found that post-treatment patients in the testosterone group had a higher reduction in FSI levels (WMD = -2.88[-6.12, 0.36]; p = 0.38; I2 = 0%). Eleven [5,8,12-14,16,17,19-22] of thirteen studies provided HbA1c levels, and pooled analysis found that testosterone treatment was linked with a greater reduction in post-treatment HbA1c levels (WMD = -0.35 [-0.64, -0.06] p = 0.17; I2 = 47.5%).

3.5. The effect on lipid parameters (Fig. 3)

All of the recruited studies have demonstrated the effect on lipid metabolism by TST. The effect on lipid metabolism was examined by considering the following parameters: total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol levels. Total cholesterol level was reported in 12 [5,8,12-16,18-22] out of 13 articles. Our meta-analysis demonstrated that cholesterol levels was reduced to a larger extent post-treatment in testosterone group compared to the placebo group (WMD = -0.28[-0.47, -0.09] p = 0.0008; I2 = 91%). On the other hand, triglyceride levels and HDL cholesterol levels were studied in all 13 [5,8,12–22] studies and showed that treatment with testosterone was associated with a significant reduction in the levels of triglyceride (WMD = -0.23 [-0.43, -0.03] p = 0.03; I2 = 79.2%) and increase in the level of HDL cholesterol (WMD = 0.07 [0.00, 0.13] p = 0.80; I2 = 0%) after treatment with testosterone. LDL cholesterol level was specified in 11 [5,8,12-16,18,19,21,22] out of 13 studies, and there was no significant difference between the pretreatment and posttreatment values among the two groups (WMD = 0.03 [-0.42, 0.48] p = 0.77; I2 = 0%)

3.6. The effect on blood pressure, body fat percentages and BMI indexes (Fig. 4)

Diastolic (DBP) and systolic blood pressure (SBP) were reported by 11 out of 13 studies [5,8,12,14–20,22] and pooled analysis revealed that treatment with testosterone was associated with a decrease in DBP (WMD = -1.04 [-2.42, 0.34] p = 0.25; I2 = 23.2%) whereas a slight increase in SBP was seen after treatment with testosterone compared to placebo (WMD = 0.42 [-5.82, 6.66] p = 0.55; I2 = 0%). In addition to the above results, our study also considered body fat, waist circumference, and BMI index. 3 out of 13 studies [15,18,19] provided body fat, and a pooling of these studies demonstrated that therapy with testosterone was linked with a reduction in body fat (WMD = -0.75 [-1.17, -0.34] p = 0.30; I2 = 6.4%). In addition, the waist circumference was reported by 10 out of 13 studies [5,8,12-16,18,21,22] that reported that testosterone therapy was related to a higher reduction in waist circumference following treatment (WMD = -0.90 [-2.36, 0.56] p = 0.03; А

	Post-	treatm	ent	Pre-	treatm	ent		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
1.1.1 Testosterone										
Heufelder (2009) [17]	1.5	0.1	16	5.6	0.3	16	7.9%	-4.10 [-4.25, -3.95]	2009	•
Gopal (2010) [16]	5.9	5.3	22	5.5	6.8	22	4.3%	0.40 [-3.20, 4.00]	2010	
Hackett (2014) [14]	4.2	2.6	91	4.1	2	91	7.7%	0.10 [-0.57, 0.77]	2014	+
Gianatti (2014) [18]	1.8	0.6	37	2.11	0.31	37	7.9%	-0.31 [-0.53, -0.09]	2014	+
Dhindsa (2015) [13]	2.7	0.5	20	3.92	0.6	20	7.8%	-1.22 [-1.56, -0.88]	2015	+
Khirpun (2018) [21]	6.3	4.8	40	9.8	5.3	40	6.0%	-3.50 [-5.72, -1.28]	2018	
Groti (2018) [22]	6.81	4.18	28	11.45	7.34	28	4.8%	-4.64 [-7.77, -1.51]	2018	
Groti (2020) [5]	5.51	4.21	28	11.45	7.34	28	4.8%	-5.94 [-9.07, -2.81]	2020 —	
Subtotal (95% CI)			282			282	51.1%	-2.27 [-4.03, -0.50]		
Heterogeneity: Tau ² = 6	5.46; Chi ^a	² = 918.	30, df=	= 7 (P <	0.0000)1); I ^z =	99%			
Test for overall effect: Z	. = 2.52 (F	P = 0.01	I)							
1.1.2 Placebo										
		0.4	40			40	7.00/	2 00 / 2 00 2 /01	2000	-
Heufelder (2009) [17]	2.5	0.1	16	6.1	0.4 8.75	16	7.9%	-3.60 [-3.80, -3.40]		
Gopal (2010) [16]		10.5 2.2	22	6.45 3.7		22 95	2.5%	1.75 [-3.96, 7.46]		
Hackett (2014) [14]	3.9	1.4	95				7.7%	0.20 [-0.48, 0.88]		
Gianatti (2014) [18]	2.6 3.8	1.4	30 14	2.78 3.92		30 14	7.8% 7.7%	-0.18 [-0.72, 0.36] -0.12 [-0.69, 0.45]		
Dhindsa (2015) [13] Groti (2018) [22]	3.0 10.18	0.9 5.6	27	3.92		27	4.7%	-0.52 [-3.76, 2.72]		
Khirpun (2018) [21]	10.16	5.9	40	10.7		40	4.7%	-0.52 [-3.76, 2.72] 1.40 [-1.14, 3.94]		
Groti (2020) [5]	6.56		40			40	5.2%	-4.26 [-7.10, -1.42]		
Subtotal (95% CI)	0.00	3.10	271	10.82	0.32	271	48.9%	-0.83 [-2.63, 0.98]	2020	
Heterogeneity: Tau ² = 5	5 61 · Chi	- 224		-7/0~	0 0000			-0.00 [-2.00, 0.00]		
Test for overall effect: Z				-70 -	0.0000	, i), i =	30 /0			
										•
Total (95% CI)			553				100.0%	-1.55 [-2.65, -0.45]		—
Heterogeneity: Tau ² = 3				f = 15 (F	P < 0.00)001); I	²=99%			-4 -2 0 2 4
Test for overall effect: Z										Decreased HOMA-IR levels Increased HOMA-IR levels
Test for subgroup diffe	rences: (Chi ² = 1	.25, df	= 1 (P =	= 0.26),	I ² = 20	.2%			
В										
	D	ost-tre	atme	nt	Pre-1	treatn	hent	Mean Di	fference	Mean Difference
Study or Subgroup		an		Total				Weight IV, Rand		
1.2.1 Testosterone			50			56	19531	gin reproduced		
Boyanov (2003) [19]		6	1.3	24	8	2.6	5 24	39% -2006	3 16 -0 841	1 2003

Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
1.2.1 Testosterone										
Boyanov (2003) [19]	6	1.3	24	8	2.6	24	3.9%	-2.00 [-3.16, -0.84]	2003	
Kapoor (2006) [18]	7.4	0.4	24	7.83	0.4	24	5.2%	-0.43 [-0.66, -0.20]	2006	-
Heufelder (2009) [17]	6.1	0.1	16	7.9	0.2	16	5.3%	-1.80 [-1.91, -1.69]	2009	-
Gopal (2010) [16]	8.6	2.7	22	7.9	4.3	22	2.4%	0.70 [-1.42, 2.82]	2010	
Jones (2011) [15]	9.2	3.8	68	9.05	3.18	68	3.9%	0.15 [-1.03, 1.33]	2011	
Gianatti (2014) [18]	7.7	3	37	7.5	0.95	37	4.1%	0.20 [-0.81, 1.21]	2014	
Hackett (2014) [14]	9.5	3.3	91	9.57	3.78	91	4.1%	-0.07 [-1.10, 0.96]	2014	
Dhindsa (2015) [13]	6.4	0.4	20	6.99	0.4	20	5.2%	-0.59 [-0.84, -0.34]	2015	
Groti (2018) [22]	8.83	1.21	28	10.06	1.44	28	4.7%	-1.23 [-1.93, -0.53]	2018	_ -
Khirpun (2018) [21]	6.3	2.2	40	8.1	3.7	40	3.6%	-1.80 [-3.13, -0.47]	2018	
Yassin (2019) [12]	4.9	0.8	229	5.3	0.8	229	5.3%	-0.40 [-0.55, -0.25]	2019	+
Groti (2020) [5]	8.23	1.09	28	10.06	1.44	28	4.7%	-1.83 [-2.50, -1.16]	2020	
Subtotal (95% CI)			627			627	52.3%	0.83 [-1.36, -0.30]		◆
Heterogeneity: Tau ² = 0	.68; Chi ^z	= 319	.38, df=	= 11 (P <	< 0.000)01); I ≊÷	= 97%			
Test for overall effect: Z	= 3.06 (F	P = 0.0	02)							
1.2.2 Placebo										
Boyanov (2003) [19]	8	2.4	24	8.4	2.8	24	3.3%	-0.40 [-1.88, 1.08]	2003	
Kapoor (2006) [18]	8.7	0.6	24	7.6	0.43	24	5.2%	1.10 [0.80, 1.40]	2006	
Heufelder (2009) [17]	6.6	0.2	16	8.3	0.2	16	5.3%	-1.70 [-1.84, -1.56]	2009	+
Gopal (2010) [16]	10.9	3.8	22	9.2	3.4	22	2.4%	1.70 [-0.43, 3.83]	2010	
Jones (2011) [15]	9.6	3.5	69	8.49	2.8	69	4.1%	1.11 [0.05, 2.17]	2011	
Hackett (2014) [14]	9.5	4	95	9.11	3.65	95	4.0%	0.39 [-0.70, 1.48]	2014	
Gianatti (2014) [18]	9.3	2.2	30	9.3	7.2	30	1.8%	0.00 [-2.69, 2.69]	2014	
Dhindsa (2015) [13]	7.3	0.7	14	6.6	0.5	14	5.0%	0.70 [0.25, 1.15]	2015	
Groti (2018) [22]	9.47	1.31	27	9.6	1.44	27	4.6%	-0.13 [-0.86, 0.60]	2018	
Khirpun (2018) [21]	8.8	5	40	8.7	5	40	2.3%	0.10 [-2.09, 2.29]	2018	
Yassin (2019) [12]	5.7	1.33	87	4.9	1.3	87	5.1%	0.80 [0.41, 1.19]	2019	
Groti (2020) [5]	8.57	1.17	27	9.6	1.44	27	4.7%	-1.03 [-1.73, -0.33]	2020	- _
Subtotal (95% CI)			475			475	47.7%	0.19 [-0.77, 1.16]		-
Heterogeneity: Tau ² = 2	.52; Chi ^z	= 454	.91, df=	= 11 (P <	< 0.000)01); F	= 98%			
Test for overall effect: Z	= 0.39 (F	P = 0.7	0)							
Total (95% CI)			1102			1102	100.0%	-0.35 [-0.79, 0.10]		◆
Heterogeneity: Tau ² = 0	.97; Chi ^z	= 792	.08, df=	= 23 (P <	< 0.000)01); P	= 97%		-	-2 -1 0 1 2
Test for overall effect: Z	= 1.53 (F	^o = 0.1	2)							-2 -1 0 1 2 Decreased FPG Increased FPG
Test for subgroup differ				= 1 (P =	0.07)	I ² = 69	7%			Decreased FPG Increased FPG

Fig. 2. Effects on Glucometabolism; A = HOMA-IR (Homeostatic model assessment for insulin resistance), B = FSG (Fasting serum glucose), C = FSI (Fasting serum insulin), D = HbA1C (Glycated hemoglobin), WMD = weighted mean difference, CI = confidence interval.

I2 = 79.2%). BMI index was included in 11 out of 13 researches [5,8,13–16,18–22], and our analysis revealed that Testosterone therapy was related to a higher reduction after follow-up than placebo (WMD = -0.16 [-0.45, 0.14] p = 0.58; I2 = 0%).

3.7. The effects on AMS and IIEF scores (Fig. 5)

Only 3 of 13 studies [12,14,15] reported AMS and IIEF scores, and their pooled analysis revealed that treatment with testosterone was related with a significant increase in IIEF scores (WMD = 2.59

С

								14 D.107		
		treatme			treatme			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	lotal	Mean	SD	lotal	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
1.3.1 Testosterone										
Kapoor (2006) [18]	11.8	1.8		13.68	1.95	24	8.3%	-1.88 [-2.94, -0.82]	2006	
Heufelder (2009) [17]	5.6	0.3	16		0.63	16		-13.43 [-13.77, -13.09]		•
Gopal (2010) [16]	14.5	9.9	22	12.8	8.95	22	6.7%	1.70 [-3.88, 7.28]	2010	
Jones (2011) [15]	18.9	16.4	68	20.88	22.83	68	6.2%	-1.98 [-8.66, 4.70]	2011	
Gianatti (2014) [18]	11.9	5	37	14.9	2.24	37	8.2%	-3.00 [-4.77, -1.23]	2014	
Dhindsa (2015) [13]	9.9	1.8	20	13.6	3	20	8.2%	-3.70 [-5.23, -2.17]	2015	
Groti (2018) [22]	17.51	10.7	28	26.03	15.86	28	6.0%	-8.52 [-15.61, -1.43]	2018	
Subtotal (95% CI)			215			215	51.9%	-4.47 [-10.22, 1.28]		
Heterogeneity: Tau² = 🤅	55.87; Ch	ii² = 655	.68, df	= 6 (P <	0.0000	1); I ^z =	99%			
Test for overall effect: Z	. = 1.52 (F	P = 0.13))							
1.3.2 Placebo										
Kapoor (2006) [18]	12.4	2.1	24	12.37	1.87	24	8.3%	0.03 [-1.09, 1.15]	2006	+
Heufelder (2009) [17]	8.4	0.4	16	16.8	0.87	16	8.3%	-8.40 [-8.87, -7.93]	2009	+
Gopal (2010) [16]	16	19.3	22	17.86	24.72	22	3.5%	-1.86 [-14.97, 11.25]	2010	
Jones (2011) [15]	19	15	69	18.17	15.7	69	6.9%	0.83 [-4.29, 5.95]	2011	
Gianatti (2014) [18]	18.4	12.7	30	17.89	3.65	30	7.1%	0.51 [-4.22, 5.24]	2014	
Dhindsa (2015) [13]	13.9	4	14	11.8	2.2	14	8.0%	2.10 [-0.29, 4.49]	2015	
Groti (2018) [22]	24.38	12.82	27	24.89	13.9	27	6.0%	-0.51 [-7.64, 6.62]	2018	
Subtotal (95% CI)			202			202	48.1%	-1.10 [-5.99, 3.79]		
Heterogeneity: Tau ² = 3	36.33; Ch	i² = 260	.57, df	= 6 (P <	0.0000	1); l² =	98%			
Test for overall effect: Z										
Total (95% CI)			417			417	100.0%	-2.88 [-6.12, 0.36]		
Heterogeneity: Tau ² = 3	32.69; Ch	i²=125	1.19, c	f= 13 (F	> < 0.00	001); P	² = 99%			
Test for overall effect: Z										-10 -5 0 5 10 Decreased FSI Increased FSI
Test for subaroup diffe	,		e	= 1 (P =	0.38), I ^z	= 0%				Decreased FSF Increased FSF

D

Mean Difference Post-treatment Pre-treatment Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% Cl Year IV, Random, 95% CI 1.4.1 Testosterone Boyanov (2003) [19] 10.4 4.0% -1.80 [-2.55, -1.05] 8.6 24 1.6 24 2003 1 Heufelder (2009) [17] -1.20 [-1.27, -1.13] 6.3 0.1 7.5 5.5% 2009 16 0.1 16 Gopal (2010) [16] 2.7% 6.3 2 22 6.43 22 -0.13 [-1.37, 1.11] 2010 2.2 Gianatti (2014) [18] 7.1 1 37 6.8 0.3 37 5.2% 0.30 [-0.04, 0.64] 2014 Hackett (2014) [14] 7.7 1.3 91 7.7 1.3 91 5.1% 0.001-0.38.0.381 2014 Dhindsa (2015) [13] 7.2 0.9 0.40 [-0.16, 0.96] 20 6.8 0.9 20 4.6% 2015 Groti (2018) [22] 7.18 0.81 8.12 1.04 4.8% -0.94 [-1.43, -0.45] 28 28 2018 0.00 [-0.27, 0.27] Hackett (2018) [20] 175 7.6 175 7.6 1.3 1.3 5.3% 2018 -1.10 [-2.05, -0.15] Khirpun (2018) [21] 78 3.5% 67 1.9 40 24 40 2018 Yassin (2019) [12] 5.6 0.2 229 5.9 0.2 229 5.6% -0.30 [-0.34, -0.26] 2019 Groti (2020) [5] 6.6 0.77 28 8.12 1.04 28 4.8% -1.52 [-2.00, -1.04] -0.55 [-0.95, -0.15] 2020 710 51.2% Subtotal (95% CI) 710 Heterogeneity: Tau² = 0.38; Chi² = 590.88, df = 10 (P < 0.00001); l² = 98% Test for overall effect: Z = 2.71 (P = 0.007) 1.4.2 Placebo Boyanov (2003) [19] 9.9 1.4 24 10.3 24 3.8% -0.40 [-1.25, 0.45] 1.6 2003 Heufelder (2009) [17] 7.1 0.1 16 7.5 0.1 16 5.5% -0.40 [-0.47, -0.33] 2009 Gopal (2010) [16] 6.3 2.7 22 7.69 2.77 22 2.0% -1.39 [-3.01, 0.23] 2010 Gianatti (2014) [18] 7.2 0.7 30 0.2 0.10 [-0.16, 0.36] 7.1 30 5.3% 2014 Hackett (2014) [14] 7.5 1.2 95 95 5.2% 0.00 [-0.34, 0.34] 7.5 1.2 2014 Dhindsa (2015) [13] 7.1 14 0.10 [-0.97, 1.17] 1.5 14 7 1.4 3.1% 2015 0.7 27 0.77 27 Groti (2018) [22] 7.65 7.89 5.0% -0.24 [-0.63, 0.15] 2018 7.5 Hackett (2018) [20] 7.5 1.5 362 1.5 362 5.4% 0.00 [-0.22, 0.22] 2018 0.50 [-0.71, 1.71] Khirpun (2018) [21] 8.4 3.1 40 7.9 2.4 40 2.8% 2018 Yassin (2019) [12] 6.53 0.22 87 5.9 0.2 87 5.6% 0.63 [0.57, 0.69] 2019 Groti (2020) [5] 27 27 5.0% 0.96 [-1.36, -0.56] 6.93 0.72 7.89 0.77 2020 Subtotal (95% CI) 744 744 48.8% -0.14 [-0.56, 0.28] Heterogeneity: Tau² = 0.41; Chi² = 510.19, df = 10 (P < 0.00001); l² = 98% Test for overall effect: Z = 0.65 (P = 0.51) Total (95% CI) 1454 1454 100.0% -0.35 [-0.64, -0.06] Heterogeneity: Tau² = 0.39; Chi² = 1611.16, df = 21 (P < 0.00001); l² = 99% 5 Ó Test for overall effect: Z = 2.38 (P = 0.02) Decreased HbA1c Increased HbA1c Test for subgroup differences: Chi² = 1.90, df = 1 (P = 0.17), I² = 47.5%

Fig. 2. (continued).

7

Descargado para Lucia Angulo (lu.maru26@gmail.com) en National Library of Health and Social Security de ClinicalKey.es por Elsevier en agosto 19, 2022. Para uso personal exclusivamente. No se permiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.

A

		reatm			reatm			Mean Difference			Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year		IV, Random, 95% Cl
1.6.1 Testosterone											
Boyanov (2003) [19]	5.4	1.5	24		1.41	24	2.7%	-0.10 [-0.92, 0.72]	2003		
Kapoor (2006) [18]	4.8	0.2	24	5.11	0.17	24	5.4%	-0.31 [-0.42, -0.20]			
Gopal (2010) [16]	4.4	0.9	22	4.7	0.9	22	3.8%	-0.30 [-0.83, 0.23]	2010		
Jones (2011) [15]	4.3	1.1	68	4.51	1.17	68	4.5%	-0.21 [-0.59, 0.17]			
Gianatti (2014) [18]	3.7	0.8	37	4.2	0.25	37	4.9%	-0.50 [-0.77, -0.23]			
Hackett (2014) [14]	3.9	0.8	91	4.15	2	91	4.2%	-0.25 [-0.69, 0.19]	2014		
Dhindsa (2015) [13]	3.8	0.7	20	4.06	0.98	20	3.8%	-0.26 [-0.79, 0.27]			
Hackett (2018) [20]	4.2	1.1	175	4.5	1.1	175	5.1%	-0.30 [-0.53, -0.07]			
Khirpun (2018) [21]	5.1	1.2	40	6.1	1.2	40	3.8%	-1.00 [-1.53, -0.47]	2018		
Groti (2018) [22]	4.62	0.63	28	5.31	0.91	28	4.3%	-0.69 [-1.10, -0.28]			
Yassin (2019) [12]	5.6	1.2	229	6.9	1.2	229	5.1%	-1.30 [-1.52, -1.08]			
Groti (2020) [5]	4.34	0.61	28	5.31	0.91	28	4.4%	-0.97 [-1.38, -0.56]	2020		
Subtotal (95% CI)			786			786	52.0%	-0.54 [-0.78, -0.29]			-
Heterogeneity: Tau² = (÷11 (P ∘	< 0.000	001); P	= 86%				
Fest for overall effect: Z	Z = 4.30	(P < 0.I	0001)								
1.6.2 Placebo											
Boyanov (2003) [19]	5.6	1.5	24	5.59	1.49	24	2.6%	0.01 [-0.84, 0.86]	2003		
Kapoor (2006) [18]	5.1	0.2	24	4.95	0.15	24	5.4%	0.15 [0.05, 0.25]	2006		
Gopal (2010) [16]	4.4	1.6	22	4	1	22	2.8%	0.40 [-0.39, 1.19]	2010		
Jones (2011) [15]	4.5	1	69	4.55	1.01	69	4.7%	-0.05 [-0.39, 0.29]	2011		
Gianatti (2014) [18]	4.3	1.03	30	4.5	0.3	30	4.5%	-0.20 [-0.58, 0.18]	2014		
Hackett (2014) [14]	4.1	1.1	95	3.7	2.6	95	3.7%	0.40 [-0.17, 0.97]	2014		
Dhindsa (2015) [13]	4	0.8	14	4.03	0.95	14	3.3%	-0.03 [-0.68, 0.62]	2015		
Groti (2018) [22]	4.89	0.74	27	5.31	0.97	27	4.1%	-0.42 [-0.88, 0.04]	2018		
Hackett (2018) [20]	4.1	1.1	362	4.1	1	362	5.3%	0.00 [-0.15, 0.15]	2018		
Khirpun (2018) [21]	5.5	1.8	40	5.9	1.5	40	3.0%	-0.40 [-1.13, 0.33]			
Yassin (2019) [12]	7.2	1.43	87	6.4	1.4	87	4.3%	0.80 [0.38, 1.22]			
Groti (2020) [5]	4.41	0.65	27	5.11	0.85	27	4.4%	-0.70 [-1.10, -0.30]	2020		
Subtotal (95% CI)			821			821	48.0%	-0.01 [-0.20, 0.18]			-
Heterogeneity: Tau² = (Test for overall effect: 2				: 11 (P «	< 0.000)1); l²=	72%				
	0.07	(1 = 0									
Total (95% CI)			1607				100.0%	-0.28 [-0.47, -0.09]			•
Heterogeneity: Tau ² = (= 23 (P	< 0.00	0001); F	* = 90%			_	-1 -0.5 0 0.5 1
Test for overall effect: Z											Decreased total cholestrol increased total cholestrol
Test for subgroup diffe	rences:	Chi ^z =	11.16,	df = 1 (F	e = 0.01	008), I ž	= 91.0%				
6											
		st-trea				tment		Mean Differen			Mean Difference
Study or Subgroup	Mea	n s	U IO	al Me	an	SD TO	nal we	ight IV, Random, 95	% CI	rear	IV, Random, 95% Cl
1.5.1 Testosterone						~-					
Boyanov (2003) [19]	1.9					.87		.0% 0.20 [-0.25, 0	-	2003	
Kapoor (2006) [18]	2.5					.25		.9% -0.34 [-0.48, -0	-	2006	
Heufelder (2009) [17]	1.	8 0	.4	16 3	8.2 (0.1		.8% -1.40 [-1.60, -1	.20]	2009	
Gopal (2010) [16]	1.3	7 0.4	43 3	22 1	.8 1	0.6	22 4	.5% -0.43 [-0.74, -0	0.12]	2010	
Jones (2011) [15]	1.	9 1.1	7 1	68 2.	06 1.	58	68 4	.0% -0.16 [-0.63, 0	0.31]	2011	
Gianatti (2014) [18]	1.	4 0.7	4	37 1	.6 0.	32	37 4	.7% -0.20[-0.46,0	0.061	2014	+
Hackett (2014) [14]	1.			31		1.5		.2% -0.10[-0.49.0		2014	
Dhindsa (2015) [13]	2.1					2.2		.8% -0.33 [-1.52, (
Groti (2018) [22]	2.3					49		.2% -0.54 [-1.21, 0		2018	
Hackett (2018) [20]	2.0							.4% 0.10 [-0.25, 0			i
<hirpun (2018)="" [21]<="" td=""><td>1.</td><td></td><td></td><td></td><td></td><td>1.7</td><td></td><td>.4% -0.70 [-1.33, -0</td><td></td><td></td><td></td></hirpun>	1.					1.7		.4% -0.70 [-1.33, -0			
Killipuli (2010) [21] Vaccin (2010) [12]	2							.4% -0.70[-1.33,-0 .060[.0660			

2.3 0.9 229 1.86 0.78 28 4.9% 3.4% Yassin (2019) [12] 2.8 0.9 229 Groti (2020) [5] 1.86 0.78 2.86 1.49 28 Subtotal (95% CI) 802 802 52.2%

Heterogeneity: Tau² = 0.20; Chi² = 115.75, df = 12 (P < 0.00001); l² = 90% Test for overall effect: Z = 3.00 (P = 0.003)

1.5.2 Placebo Boyanov (2003) [19] 1.7 0.85 1.9 0.92 3.8% -0.20 [-0.70, 0.30] 2003 24 24 Kapoor (2006) [18] 2.76 0.26 24 2.7 0.2 24 5.0% 0.06 [-0.07, 0.19] 2006 Heufelder (2009) [17] 2.6 0.4 16 3.4 0.3 16 4.7% -0.80 [-1.04, -0.56] 2009 Gopal (2010) [16] 2.19 1.84 22 1.6 0.78 22 2.7% 0.59 [-0.25, 1.43] 2010 Jones (2011) [15] Gianatti (2014) [18] 219 69 2.05 69 4.0% 0.14 [-0.33, 0.61] 1 4 9 1.3 2011 1.8 0.27 2 1.1 1.19 30 30 4.1% 0.00 [-0.44, 0.44] 2014 1.8 Hackett (2014) [14] 2.1 1.3 95 95 4.4% 0.10 [-0.24, 0.44] 2014 Dhindsa (2015) [13] 1.94 1.13 14 1.88 1 14 2.8% 0.06 [-0.73, 0.85] 2015 Groti (2018) [22] 3.02 2.08 27 3.52 3.15 27 1.4% -0.50 [-1.92, 0.92] 2018 Hackett (2018) [20] 1.2 1.5 1.9 1.2 1.6 0.10 [-0.07, 0.27] 2 362 362 4.9% 2018 2.2 2.3 Khirpun (2018) [21] 40 40 3.2% 2018

2.2

2.94 1.79

1.1

87

27

4.5%

2.5%

Groti (2020) [5] Subtotal (95% Cl) 27 837 837 47.8% Heterogeneity: Tau² = 0.10; Chi² = 56.97, df = 12 (P < 0.00001); l² = 79% Test for overall effect: Z = 0.19 (P = 0.85)


1.11

87

2.7

2.42 1.53

Yassin (2019) [12]



0.50 [0.17, 0.83]

-0.52 [-1.41, 0.37]

-0.02 [-0.25, 0.20]

-0.50 [-0.66, -0.34] 2019

2020

2019

2020

-1.00 [-1.62, -0.38]

-0.41 [-0.69, -0.14]

Fig. 3. Effects on lipid parameters; A = Total serum cholesterol, B = triglycerides, C = HDL (high density lipoprotein), D = LDL (LDL cholesterol), WMD = weighted mean difference, CI = confidence interval.

[-3.22, 8.39] p = 0.04; I2 = 75.6% but a decrease in AMS (WMD = -6.45 [-16.25, 3.35] p = 0.10; I2 = 62.3%)

3.8. Mortality (Fig. 6)

The data on mortality was reported by only two studies [14,20] and their pooling revealed that testosterone therapy was associated

С

	Post-	treatm			reatm			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
1.7.1 Testosterone										
Boyanov (2003) [19]	1.21	0.22	24	1.2	0.12	24	3.9%	0.01 [-0.09, 0.11]	2003	
Kapoor (2006) [18]	0.97	0.04	24	1.02	0.04	24	4.3%	-0.05 [-0.07, -0.03]	2006	+
Heufelder (2009) [17]	1.4	0.1	16	1.05	0.03	16	4.2%	0.35 [0.30, 0.40]	2009	
Gopal (2010) [16]	0.97	0.17	22	0.82	0.14	22	4.0%	0.15 [0.06, 0.24]	2010	
Jones (2011) [15]	1.09	0.3	68	1.19	0.3	68	3.9%	-0.10 [-0.20, 0.00]	2011	
Gianatti (2014) [18]	1.2	0.3	91	1.1	0.1	91	4.1%	0.10 [0.04, 0.16]	2014	
Hackett (2014) [14]	1	0.27	37	1.15	0.65	37	2.7%	-0.15 [-0.38, 0.08]	2014	
Dhindsa (2015) [13]	0.85	0.21	20	0.87	0.18	20	3.7%	-0.02 [-0.14, 0.10]	2015	
Groti (2018) [22]	1.04	0.21	28	1.01	0.22	28	3.8%	0.03 [-0.08, 0.14]	2018	
Hackett (2018) [20]	1.1	0.29	175	1.1	0.3	175	4.2%	0.00 [-0.06, 0.06]	2018	-+-
<hirpun (2018)="" [21]<="" td=""><td>1.52</td><td>0.13</td><td>40</td><td>1.41</td><td>0.12</td><td>40</td><td>4.2%</td><td>0.11 [0.06, 0.16]</td><td>2018</td><td></td></hirpun>	1.52	0.13	40	1.41	0.12	40	4.2%	0.11 [0.06, 0.16]	2018	
Yassin (2019) [12]	1.4	0.3	229	1.1	0.3	229	4.2%	0.30 [0.25, 0.35]	2019	
Groti (2020) [5]	1.15	0.22	28	1.01	0.22	28	3.8%	0.14 [0.02, 0.26]	2020	
Subtotal (95% CI)			802			802	51.0%	0.07 [-0.02, 0.17]		
Heterogeneity: Tau ² = 0).03; Chi ^a	= 316	29, df=	= 12 (P <	0.000	001); F	= 96%			
Test for overall effect: Z	= 1.56 (F	P = 0.1	2)							
1.7.2 Placebo										
Boyanov (2003) [19]	1.18	0.23	24	1.16	0.21	24	3.7%	0.02 [-0.10, 0.14]	2003	
<apoor (2006)="" [18]<="" td=""><td>1.02</td><td>0.04</td><td>24</td><td>1.04</td><td>0.04</td><td>24</td><td>4.3%</td><td>-0.02 [-0.04, 0.00]</td><td></td><td>-</td></apoor>	1.02	0.04	24	1.04	0.04	24	4.3%	-0.02 [-0.04, 0.00]		-
Heufelder (2009) [17]	1.02	0.04	16	1.04	0.05	16	4.2%	0.20 [0.15, 0.25]		
Gopal (2010) [16]	0.87	0.34	22	0.8	0.27	22	3.1%	0.07 [-0.11, 0.25]		
Jones (2011) [15]	1.21	0.27	69	1.16	0.31	69	3.9%	0.05 [-0.05, 0.15]		
Hackett (2014) [14]	1.06	0.3	95	1.09	0.33	95	4.0%	-0.03 [-0.12, 0.06]		
Gianatti (2014) [14]	1.1	0.3	30	1.00	0.00	30	3.8%	0.10 [-0.01, 0.21]		
Dhindsa (2015) [13]	1.03	0.31	14	1	0.25	14	2.9%	0.03 [-0.18, 0.24]		
Groti (2018) [22]	1.07	0.29	27	1.05	0.32	27	3.3%	0.02 [-0.14, 0.18]		
Hackett (2018) [20]	1.8	0.3	362	1.4	0.4	362	4.2%	0.40 [0.35, 0.45]		
Khirpun (2018) [21]	1.43	0.13	40	1.42	0.12	40	4.2%	0.01 [-0.04, 0.06]		
Yassin (2019) [12]	1.43	0.41	87	1.4	0.4	87	3.7%	-0.20 [-0.32, -0.08]		
Groti (2020) [5]	1.08	0.21	27	1.04	0.26	27	3.7%	0.04 [-0.09, 0.17]		
Subtotal (95% Cl)	1.00	0.21	837	1.04	0.20	837	49.0%	0.06 [-0.04, 0.15]	2020	-
Heterogeneity: Tau ² = 0	1.03: Chi ^a	= 265	79. df=	= 12 (P <	< 0.000	001): P	= 95%			-
Test for overall effect: Z					2.000					
Total (95% CI)			1639			1639	100.0%	0.07 [0.00, 0.13]		
Heterogeneity: Tau ² = (1.02: Chie	- 602		- 26 /0 /				0.07 [0.00, 0.15]	_	
Heterogeneity. Tau-= t Test for overall effect: Z				- 20 (P**	- 0.00t	юц, с:	- 30 %			-0.2 -0.1 Ó 0.1 0.2
rest for overall effect. Z										Decreased HDL Increased HDL

Test for subgroup differences: Chi² = 0.07, df = 1 (P = 0.80), l² = 0%

D

	Post-t				reatmo			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
1.8.1 Testosterone										
Boyanov (2003) [19]	3.6	1.25	24	3.57	1.14	24	4.3%	0.03 [-0.65, 0.71]	2003	3
Kapoor (2006) [18]	2.74	0.18	24	0.79	0.15	24	4.7%	1.95 [1.86, 2.04]	2006	ĵ
Gopal (2010) [16]	3.22	0.66	22	2.78	0.79	22	4.5%	0.44 [0.01, 0.87]	2010) – – – – – – – – – – – – – – – – – – –
Jones (2011) [15]	2.49	0.82	68	2.78	0.99	68	4.6%	-0.29 [-0.60, 0.02]	2011	
Gianatti (2014) [18]	2	0.59	37	2.3	0.27	37	4.7%	-0.30 [-0.51, -0.09]	2014	4
Hackett (2014) [14]	2.11	0.69	91	2.21	0.81	91	4.7%	-0.10 [-0.32, 0.12]	2014	4 •
Dhindsa (2015) [13]	1.99	0.59	20	2.25	0.95	20	4.5%	-0.26 [-0.75, 0.23]	2015	5
Groti (2018) [22]	2.7	0.59	28	2.79	0.77	28	4.6%	-0.09 [-0.45, 0.27]	2018	3
Khirpun (2018) [21]	2.86	1.04	40	3.41	1.28	40	4.5%	-0.55 [-1.06, -0.04]	2018	3
Yassin (2019) [12]	3.2	0.7	229	4.1	0.7	229	4.7%	-0.90 [-1.03, -0.77]	2019	a —•
Groti (2020) [5]	2.39	0.56	28	2.79	0.77	28	4.6%	-0.40 [-0.75, -0.05]	2020	
Subtotal (95% Cl)			611			611	50.3%	-0.04 [-0.90, 0.82]		
Heterogeneity: Tau ² =	2.08; Ch	i ² = 15-	44.73, (df = 10 (P < 0.0	0001);	I [≈] = 99%			
Test for overall effect:	Z = 0.09	(P = 0.9	93)							
1.8.2 Placebo										
Boyanov (2003) [19]	3.69	1.3	24	3.61	1.22	24	4.2%	0.08 [-0.63, 0.79]	2003	3
Kapoor (2006) [18]	2.81	0.17	24	2.04	0.16	24	4.7%	0.77 [0.68, 0.86]	2006	j —
Gopal (2010) [16]	2.91	1.37	22	2.45	0.86	22	4.3%	0.46 [-0.22, 1.14]	2010)
Jones (2011) [15]	2.5	0.7	69	2.61	0.91	69	4.6%	-0.11 [-0.38, 0.16]	2011	· · · · · · · · · · · · · · · · · · ·
Hackett (2014) [14]	2.14	0.86	95	2.19	0.91	95	4.7%	-0.05 [-0.30, 0.20]	2014	·
Gianatti (2014) [18]	2.1	0.82	30	2.2	0.25	30	4.6%	-0.10 [-0.41, 0.21]	2014	•
Dhindsa (2015) [13]	2.12	0.72	14	2.1	0.59	14	4.5%	0.02 [-0.47, 0.51]	2015	5
Groti (2018) [22]	2.54	0.54	27	2.8	0.95	27	4.5%	-0.26 [-0.67, 0.15]	2018	3
Khirpun (2018) [21]	3.34	1.32	40	3.35	1.3	40	4.4%	-0.01 [-0.58, 0.56]	2018	3
Yassin (2019) [12]	3.9	0.92	87	3.4	0.9	87	4.6%	0.50 [0.23, 0.77]	2019	a – – – – – – – – – – – – – – – – – – –
Groti (2020) [5]	2.39	0.68	27	2.67	0.67	27	4.6%	-0.28 [-0.64, 0.08]	2020	
Subtotal (95% CI)			459			459	49.7%	0.10 [-0.22, 0.41]		
Heterogeneity: Tau ² =	0.24; Ch	i ² = 123	2.71, dt	r=10 (P	< 0.00	i001); P	°= 92%			
Test for overall effect:	Z = 0.59	(P = 0.9)	55)							
Total (95% CI)			1070			1070	100.0%	0.03 [-0.42, 0.48]		
Heterogeneity: Tau ² =	1.12; Ch	i ² = 16	73.15.	df = 21 (P < 0.0	0001):	I ² = 99%			
Test for overall effect:										-1 -0.5 Ó 0.5 1 Decreased LDL Increased LDL

Fig. 3. (continued).

9

Descargado para Lucia Angulo (lu.maru26@gmail.com) en National Library of Health and Social Security de ClinicalKey.es por Elsevier en agosto 19, 2022. Para uso personal exclusivamente. No se permiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.

A

	Post	treatm	ent	Pre-	treatme	ent		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.13.1 Testosterone									
Boyanov (2003) [19]	82	4	24	80	4	24	4.7%	2.00 [-0.26, 4.26]	
Gianatti (2014) [18]	73	7.4	37	72	2.5	37	4.5%	1.00 [-1.52, 3.52]	
Gopal (2010) [16]	79.2	2.9	22	82	6.93	22	4.2%	-2.80 [-5.94, 0.34]	
Groti (2018) [22]	78.14	10.08	28	77.5	5.85	28	3.5%	0.64 [-3.68, 4.96]	
Groti (2020) [5]	77.32	6.24	28	77.5	5.85	28	4.2%	-0.18 [-3.35, 2.99]	
Hackett (2014) [14]	78.9	10.1	91	79.4	9.4	91	4.4%	-0.50 [-3.33, 2.33]	
Hackett (2018) [20]	77.4	10.4	175	81.4	10.4	175	4.7%	-4.00 [-6.18, -1.82]	
Heufelder (2009) [17]	80	1	16	85.6	0.9	16	5.3%	-5.60 [-6.26, -4.94]	
Jones (2011) [15]	82.8	9.7	68	82.5	10.23	68	4.1%	0.30 [-3.05, 3.65]	
Kapoor (2006) [18]	72.6	1.5	24	74	1.4	24	5.2%	-1.40 [-2.22, -0.58]	
Yassin (2019) [12]	73.1	8.91	229	81.2	8.9	229	5.0%	-8.10 [-9.73, -6.47]	•
Subtotal (95% Cl)			742			742	49.6%	-1.87 [-3.86, 0.12]	
Heterogeneity: Tau ² = 9	.65; Chi ^a	² = 146.9	30, df =	10 (P <	0.0000	1); l² =	93%		
Test for overall effect: Z	= 1.84 (P = 0.07)						
1.13.2 Placebo									
Bovanov (2003) (19)	80	4	24	76	6	24	4.3%	4.00 [1.12, 6.88]	│ <u> </u>
Gianatti (2014) [18]	76	7.4	30	80	3	30	4.3%	-4.00 [-6.86, -1.14]	← → → →
Gopal (2010) [16]	80	4.7	22	79	3.16	22	4.6%	1.00 [-1.37, 3.37]	
Groti (2018) [22]	78.7		27		5.25	27	3.5%	-0.19 [-4.59, 4.21]	
Groti (2020) [5]	80	2.5	27		5.25	27	4.7%	1.11 [-1.08, 3.30]	
Hackett (2014) [14]	77.3	8.8	95	77.5	8.9	95	4.5%	-0.20 [-2.72, 2.32]	
Hackett (2018) [20]	74	10.31	362	78.2	10.4	362	5.0%	-4.20 [-5.71, -2.69]	
Heufelder (2009) [17]	81	1	16	85	1	16	5.3%	-4.00 [-4.69, -3.31]	_ - _
Jones (2011) [15]	80.3	9.8	69	81.6	9.5	69	4.1%	-1.30 [-4.52, 1.92]	
Kapoor (2006) [18]	72.7	1.7	24	74	1.4	24	5.2%	-1.30 [-2.18, -0.42]	
Yassin (2019) [12]	92.1	6.88	87	84.7	6.7	87	4.8%	7.40 [5.38, 9.42]	
Subtotal (95% CI)			783			783	50.4%	-0.20 [-2.26, 1.86]	
Heterogeneity: Tau ² = 1	0.60; Ch	ni ² = 161	.11, df	= 10 (P	< 0.000	01); I ₹÷	= 94%		
Test for overall effect: Z	= 0.19 (P = 0.85)						
Total (95% CI)			1525			1525	100.0%	-1.04 [-2.42, 0.34]	-
Heterogeneity: Tau ² = 9	.26; Chi ^a	² = 333.6	34. df=	21 (P <	0.0000	1); l² =	94%		
Test for overall effect: Z									-4 -2 0 2 4 Decreased DBP Increased DBP
Test for subgroup differ			e	= 1 (P =	0.25), I ^z	= 23.2	%		Decreased DBP Increased DBP

Fig. 4. Effects on blood pressure, body fat percentages and BMI indexes; A = DBP (Diastolic blood pressure), B= SBP (Systolic blood pressure), C= Body fat, D = Waist circumference, E = BM1.

with a significant decrease in mortality risk compared to placebo $(RR = 0.21 \ [0.10, 0.46] \ p = 0.0001; \ I2 = 0\%)$

3.9. The effects on hormonal levels (Fig. 7)

To evaluate the influence of testosterone on the level of hormones following variables were taken into consideration: total testosterone, free testosterone, SHBG and PSA. 7 publications [5,12,13,18,19,21,22] had included total testosterone levels, and the pooled analysis showed that testosterone therapy is related to a significant rise in total testosterone levels (WMD = 5.08 [2.90, 7.26] p = 0.0002; I2 = 92.9%). Excluding the studies one-by-one from the pooled analysis did not reduce the in-study heterogeneity.

Free testosterone levels were evaluated in 3 papers [13,14,21], and their pooling indicated a substantially larger increase in the patients who got testosterone therapy than placebo (WMD = 81.21 [23.87, 138.54] p = 0.07; I2 = 70%). SHBG level was included in 4 studies [13,17,21,22] and pooling revealed a higher drop in SHBG level was associated with treatment with testosterone (WMD = -3.24 [-6.33, -0.14] p = 0.80; I2 = 0%). PSA levels were evaluated in 6 studies [8,13–15,17,21], and their analysis found no clinically significant difference in the PSA levels after therapy among the two groups (WMD = 0.06 [-0.02, 0.13] p = 0.47; I2 = 0%)

4. Discussion

Numerous studies have demonstrated the association between T2DM and hypogonadism. Hypogonadism is more prevalent in T2DM patients than in the general population, which may be due to the activation of the insulin signalling pathway [6]. This comprehensive systematic review and meta-analysis of 13 studies comprising of 1596 patients compared outcomes of testosterone supplemental therapy group versus control arm group in hypogonadal males with type 2 diabetes mellitus (T2DM). According to guidelines of Society of Endocrinology, testosterone treatment is required to reverse or prevent the symptoms and long-term effects of male hypogonadism because it induces or completes secondary sexual development; improves sex drive, libido, and sexual function; improves mood and well-being; improves muscle mass and strength; restores or maintains masculine characteristics, such as facial and body hair; and maintains bone strength and prevents osteoporosis and anaemia [24]. Considering the glycometabolic effects, testosterone therapy group patients had reduction in HOMA-IR levels, FSG, FSI and HBA1C as shown by previous studies [5,6,8,13,14,16,17,21–23]. While the insulin-sensitizing effect of testosterone has been observed in type 2 diabetics, studies in nonobese men or those with low normal testosterone concentrations sometimes fail to show an impact on insulin sensitivity. Recent research on testosterone replacement in hypogonadal patients with type 2 diabetes has shown promising results [25]. A study

B

	Post	treatme	nt	Pre-t	reatme	ent		Mean Diffe	rence		Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Randon	n. 95% Cl		IV, Random, 95% Cl	
1.12.1 Testosterone							<u> </u>		,		· · · · ·	
Boyanov (2003) [19]	120	10	24	122	8	24	4.5%	-2.00 [-7.	12 3 1 21			
Gianatti (2014) [18]	140		37	140	5	27	4.6%		27, 4.27]			
Gopal (2010) [16]	115.3			115.83	5.15		4.6%	-0.53 [-4.				
Groti (2018) [22]		13.65		134.64		28	4.4%	4.15 [-2.2				
Groti (2020) [5]	133.75			134.64		28	4.5%	-0.89 [-6.			-	
Hackett (2014) [14]	142.3		91	140.2	15.9	91	4.5%		04, 7.24]			
Hackett (2018) [20]		16.15	175	141.8	16.8	175	4.6%	-2.00 [-5.				
Heufelder (2009) [17]	138		16	104.5	2.6	16	4.7%	33.50 [32.0				•
Jones (2011) [15]	138.7		68	138.6	17.3	68	4.5%		37, 5.57			
Kapoor (2006) [18]	127.6		24	127.6	2.8	24	4.6%		58, 1.58]			
Yassin (2019) [12]		13.51	229	136.9	13.5			-11.90 [-14.3				
Subtotal (95% CI)	125	10.01	743	150.5	10.0	732	50.1%	2.07 [-9.6				
Heterogeneity: Tau² = Test for overall effect:			7.04, d1	f=10 (P	< 0.000	001); I ^z =	99%					
1.12.2 Placebo												
Boyanov (2003) [19]	122	8	24	120	8	24	4.6%	2.00 [-2.	53, 6.53]			
Gianatti (2014) [18]	140	13.3	30	140	5.25	30	4.5%	0.00 [-5.	12, 5.12]			
Gopal (2010) [16]	114.8	9.62	22	118.4	9.97	22	4.5%	-3.60 [-9.	39, 2.19]			
Groti (2018) [22]	135.93	16.99	27	138.15	13.24	27	4.3%	-2.22 [-10.	34, 5.90]			
Groti (2020) [5]	137.01	13.35	27	138.15	13.24	27	4.4%	-1.14 [-8.	23, 5.95]			
Hackett (2014) [14]	136.3	14.3	95	137.1	13	95	4.6%	-0.80 [-4.	69, 3.09]			
Hackett (2018) [20]	135	16.8	362	139.4	16.8	362	4.6%	-4.40 [-6.8				
Heufelder (2009) [17]	139	1.4	16	143.5	2.1	16	4.7%	-4.50 [-5.7			-	
Jones (2011) [15]	134.9	16.51	69	136.7	17.12	69	4.5%	-1.80 [-7.	41, 3.81]			
Kapoor (2006) [18]	127.5	2.9	24	131	3.1	24	4.6%	-3.50 [-5.2	20, -1.80]			
Yassin (2019) [12]	136		87	129.8	12.7	87	4.6%	6.20 [2.	41, 9.99]			
Subtotal (95% Cl) Heterogeneity: Tau² =	6.59; Chi²	= 37.57,	783 df = 10	(P < 0.0	001); l ^z	783 = 73%	49.9%	-1.51 [-3.	49, 0.47]			
Test for overall effect:	Z=1.49 (F	P = 0.14)										
Total (95% CI)			1526			1515	100.0%	0.42 [-5.	82, 6.66]			
Heterogeneity: Tau ² =	217.29; C	hi ^z = 212	9.97, dt	f = 21 (P	< 0.000	001); I ^z =	99%			-20	-10 0 10	20
Test for overall effect:	Z = 0.13 (F	P = 0.90)								-20	Decreased SBP Increased SBP	20
Test for subgroup diff	erences: C	;hi² = 0.3	5, df = 1	l (P = 0.5	55), I² =	0%					Decleased SDI Incleased SDI	
С												
	Post-trea	atment	Pre	-treatm	ent		Mean D	ifference			Mean Difference	
Study or Subgroup	Mean	SD Tota	al Mea	n SD	Total	Weight	IV, Rand	dom, 95% Cl	Year		IV, Random, 95% Cl	
1.9.1 Testosterone												
Boyanov (2003) [19]	30.1	6.9 6	8 31.0	4 8.28	68	2.6%	-0.94	[-3.50, 1.62]	2003			
Kapoor (2006) [18]	32.8	1.1 2	4 33.7	9 1.13	24	43.6%	-0.99 [-1.62, -0.36]	2006			
Jones (2011) [15] Subtotal (95% CI)	32.7	6.4 2 11		8 5.43	24 116	1.5% 4 7.8 %		[-4.24, 2.48]	2011	-		
Heterogeneity: Tau ² = 1	0.00°.Chi Z -			- 1 00\· IZ		47.070	-0.30 [·	-1.59, -0.38]			▼	
Test for overall effect: 2			– 2 (F –	. 1.00), 1	- 0 %							
1.9.2 Placebo												
Boyanov (2003) [19]	32.9	92	4 32.9	2 9.01	24	0.7%	-0.02	[-5.11, 5.07]	2003			_
Kapoor (2006) [18]				3 1.04	24	47.4%		-1.24, -0.02]				
Jones (2011) [15]				4 6.55	69	4.1%		[-1.69, 2.41]	2011			
Subtotal (95% CI)		11	7		117	52.2%		[1.12, 0.03]			•	
Heterogeneity: Tau² = 1 Test for overall effect: 2			= 2 (P =	: U.65); I²	= 0%							

Test for subgroup differences: Chi² = 1.07, df = 1 (P = 0.30), l² = 6.4%



compared 178 men who received long-acting testosterone undecanoate to 178 men with subnormal testosterone who were not treated. The mean follow-up was eight years, and the maximum was 11. The mean age in the testosterone group was 62 and in the untreated group was 64. The use of testosterone reduced HbA1c, fasting plasma glucose, and HOMA-IR. 90% of patients achieved a HbA1c of <7%, 83% achieved <6.5%, and 46% achieved <5.7%. In addition, 34% participants had total remission of diabetes with no anti-diabetes drugs. No diabetes recurrence was seen in the remission group after 2.5 years. Conversely, untreated men with diabetes and hypogonadism had steadily rising glycemia and HbA1c, along with rising HOMA-IR [25]. However, more interventional studies are required to fully comprehend the relationship between circulating sex hormones and carbohydrate metabolism.

Decreased Body fat Increased Body fat

In terms of serum lipid profile, four lipid parameters (total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides) were reported. Ten studies found that total cholesterol levels were lower in the testosterone group after treatment than in the placebo group. While twelve studies reported decrease in triglyceride levels and increases in HDL cholesterol levels simultaneously. However,

11

no statistically significant difference was found in LDL cholesterol levels in both groups. Considering these changes, improvement in lipid profile should result in cardioprotective effects. However, contrary results have been delineated. Testosterone treatment was reported to increase noncalcified plaque volume and total plaque volume versus placebo, instead of small LDL cholesterol, HDL

D

	Post-	reatme	nt	Pre-t	reatme	nt		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
1.10.1 Testosterone										
Kapoor (2006) [18]	113.37	2.5	24	115.1	2.4	24	6.8%	-1.73 [-3.12, -0.34]	2006	
Gopal (2010) [16]	93.58	6.39	22	93.25	7.03	22	4.7%	0.33 [-3.64, 4.30]	2010	
Jones (2011) [15]	111.9	13.79	68	112.7	13.35	68	4.3%	-0.80 [-5.36, 3.76]	2011	
Gianatti (2014) [18]	111	4.3	37	110	4.2	37	6.5%	1.00 [-0.94, 2.94]	2014	
Hackett (2014) [14]	112.8	14	91	115.1	13.1	91	4.8%	-2.30 [-6.24, 1.64]	2014	
Dhindsa (2015) [13]	126	18	20	128	20	20	1.3%	-2.00 [-13.79, 9.79]	2015	
Groti (2018) [22]	114.9	5.49	28	116.48	5.07	28	5.8%	-1.58 [-4.35, 1.19]	2018	
Khirpun (2018) [21]	108.1	8.2	40	114.3	9.5	40	4.8%	-6.20 [-10.09, -2.31]	2018	
Yassin (2019) [12]	97.4	7.4	229	104.2	7	229	6.9%	-6.80 [-8.12, -5.48]	2019	
Groti (2020) [5]	112.96	5.21	28	116.48	5.07	28	5.8%	-3.52 [-6.21, -0.83]	2020	
Subtotal (95% CI)			587			587	51.6%	-2.45 [-4.59, -0.31]		•
Heterogeneity: Tau ² =	8.69; Chi	= 58.91	1, df = 9	3 (P < 0.0	0001); I	z= 859	5			
Fest for overall effect:	Z= 2.24 (P = 0.02)							
1.10.2 Placebo										
Kapoor (2006) [18]	115.1	2.4	24	115.1	2.4	24	6.9%	0.00 [-1.36, 1.36]	2006	
Gopal (2010) [16]	83.9	14.3	22	84.1	13.86	22	2.2%	-0.20 [-8.52, 8.12]	2010	
Jones (2011) [15]	112.4	15.52	69	111.7	15.23	69	3.8%	0.70 [-4.43, 5.83]	2011	
Hackett (2014) [14]	112	12.4	95	112.6	13.3	95	5.0%	-0.60 [-4.26, 3.06]	2014	
Gianatti (2014) [18]	117	2.5	30	115	2.75	30	6.9%	2.00 [0.67, 3.33]	2014	
Dhindsa (2015) [13]	124	19	14	124	30	14	0.6%	0.00 [-18.60, 18.60]	2015	
Groti (2018) [22]	115.46	4.78	27	116.64	4.96	27	5.9%	-1.18 [-3.78, 1.42]	2018	++_
<hirpun (2018)="" [21]<="" td=""><td>115.5</td><td>10.1</td><td>40</td><td>114.7</td><td>9.8</td><td>40</td><td>4.4%</td><td>0.80 [-3.56, 5.16]</td><td>2018</td><td></td></hirpun>	115.5	10.1	40	114.7	9.8	40	4.4%	0.80 [-3.56, 5.16]	2018	
(assin (2019) [12]	108.5	9.95	87	101.1	9.9	87	5.6%	7.40 [4.45, 10.35]	2019	
Groti (2020) [5]	113	1.25	27	115	1.47	27	7.2%	-2.00 [-2.73, -1.27]	2020	+
Subtotal (95% Cl)			435			435	48.4%	0.74 [-1.15, 2.64]		◆
Heterogeneity: Tau ² =	5.85; Chř	= 58.74	4, df = 9	3 (P < 0.0	0001); I	²= 859	5			
Test for overall effect:	Z=0.77 (P = 0.44)							
Fotal (95% CI)			1022			1022	100.0%	-0.90 [-2.36, 0.56]		•
Heterogeneity: Tau ² =	7.62: Chi	= 147 5	59. df =	19 (P < I	0.00001); ² = 8	7%			
Fest for overall effect:						/1 0				-10 -5 0 5 10
Foot for overall chect.			,	- 1 /D - 0	0.00 18-	- 70 20				Decreased Waist circumference Increased Waist circumference

Test for subgroup differences: Chi# = 4.80, df = 1 (P = 0.03), I# = 79.2%

Ε

	Post-f	treatm			reatm			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.11.1 Testosterone									
Boyanov (2003) [19]	30.1	4.7	24	31.08	4.79	24	1.2%	-0.98 [-3.66, 1.70]	·
Dhindsa (2015) [13]	38.9	8.1	20	39	7.6	20	0.4%	-0.10 [-4.97, 4.77]	·
Gianatti (2014) [18]	30.9	5.4	37	31.5	1.8	37	2.5%	-0.60 [-2.43, 1.23]	
Gopal (2010) [16]	25.7	3.6	22	25.44	3.57	22	1.9%	0.26 [-1.86, 2.38]	
Groti (2018) [22]	33.25	4.77	28	34.03	4.37	28	1.5%	-0.78 [-3.18, 1.62]	· · · · · · · · · · · · · · · · · · ·
Groti (2020) [5]	32.45	4.74	28	34.03	4.37	28	1.5%	-1.58 [-3.97, 0.81]	←
Hackett (2014) [14]	32.7	5.9	91	33	6.1	91	2.7%	-0.30 [-2.04, 1.44]	
Hackett (2018) [20]	32.2	6.4	175	32.6	6.4	175	4.5%	-0.40 [-1.74, 0.94]	
Jones (2011) [15]	32.9	6.5	68	32.76	6.12	68	1.9%	0.14 [-1.98, 2.26]	
Kapoor (2006) [18]	33.6	0.9	24	33	0.86	24	21.4%	0.60 [0.10, 1.10]	_
<hirpun (2018)="" [21]<="" td=""><td>32.3</td><td>2.8</td><td>40</td><td>34</td><td>2.6</td><td>40</td><td>5.6%</td><td>-1.70 [-2.88, -0.52]</td><td></td></hirpun>	32.3	2.8	40	34	2.6	40	5.6%	-1.70 [-2.88, -0.52]	
Subtotal (95% CI)			557			557	45.0%	-0.39 [-1.05, 0.26]	
Heterogeneity: Tau ² =	0.42; Ch	i ² = 17.	00, df=	= 10 (P =	= 0.07)	; I ² = 41	%		
Test for overall effect: .	Z=1.17	(P = 0.3)	24)						
.11.2 Placebo									
3oyanov (2003) [19]	30.9	4.9		31.01	4.9	24	1.1%	-0.11 [-2.88, 2.66]	
Dhindsa (2015) [13]	40.6	8.4	14	39.4	7.6	14	0.2%	1.20 [-4.73, 7.13]	•
Gianatti (2014) [18]	33.3	2.7	30	33.4	1	30	7.2%	-0.10 [-1.13, 0.93]	
Gopal (2010) [16]	22.3	5.1	22	22.1	4.93	22	1.0%	0.20 [-2.76, 3.16]	
Groti (2018) [22]	31.96	3.73	27	32.63	3.67	27	2.2%	-0.67 [-2.64, 1.30]	
Groti (2020) [5]	31.1	1.35	27	32.63	3.67	27	3.8%	-1.53 [-3.00, -0.06]	
Hackett (2014) [14]	32.3	5.2	95	32.4	5.5	95	3.5%	-0.10 [-1.62, 1.42]	
Hackett (2018) [20]	31.2	5.8	362	31.7	5.9	362	9.9%	-0.50 [-1.35, 0.35]	
Jones (2011) [15]	31.7	5.6	69	31.56	5.87	69	2.3%	0.14 [-1.77, 2.05]	
<apoor (2006)="" [18]<="" td=""><td>33</td><td>1</td><td>24</td><td>33</td><td>0.96</td><td>24</td><td>18.7%</td><td>0.00 [-0.55, 0.55]</td><td></td></apoor>	33	1	24	33	0.96	24	18.7%	0.00 [-0.55, 0.55]	
Khirpun (2018) [21]	33.9	2.8	40	33.6	2.9	40	5.1%	0.30 [-0.95, 1.55]	
Subtotal (95% CI)			734			734	55.0%	-0.18 [-0.54, 0.18]	•
Heterogeneity: Tau ² =				10 (P =	0.86);1	² = 0%			
Test for overall effect: .	Z = 1.00	(P = 0.3	32)						
Fotal (95% CI)			1291			1291	100.0%	-0.16 [-0.45, 0.14]	•
Heterogeneity: Tau ² =	0.04; Ch	i ^z = 23.	05, df=	= 21 (P =	= 0.34)	; I Z = 99	6		
Test for overall effect: .	Z=1.04	(P = 0.3)	30)			-054300			-2 -1 U 1 2 Decreased BMI Increased BMI
Test for subgroup diffe	erences:	Chi²=	0.31, d	f=1 (P	= 0.58)), l² = 0'	%		Decreased DMI Increased DMI
						_			
						F	ig. 4. (con	ntinued).	

12


Descargado para Lucia Angulo (lu.maru26@gmail.com) en National Library of Health and Social Security de ClinicalKey.es por Elsevier en agosto 19, 2022. Para uso personal exclusivamente. No se permiten otros usos sin autorización. Copyright ©2022. Elsevier Inc. Todos los derechos reservados.

A

	Post-	treatme	ent	Pre	treatme	nt		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.14.1 Testosterone									
Hackett (2014) [14]	14	10.89	91	13.24	7.5	91	17.5%	0.76 [-1.96, 3.48]	
Jones (2011) [15]	40.9	20.34	68	32.4	18.47	68	14.8%	8.50 [1.97, 15.03]	
Yassin (2019) [12]	19.8	5.61	229	11.4	5.6	229	18.0%	8.40 [7.37, 9.43]	+
Subtotal (95% CI)			388			388	50.3%	5.70 [-0.16, 11.56]	
Heterogeneity: Tau ² =	23.11; 0	Chi ^z = 20	5.68, d	f=2(P	< 0.0000	1); I ^z = !	93%		
Test for overall effect:	Z = 1.91	(P = 0.0	J6)						
1.14.2 Placebo									
Hackett (2014) [14]	10.5	10.4	95	11.64	9	95	17.4%	-1.14 [-3.91, 1.63]	_ - +
Jones (2011) [15]	37.3	20.08	69	32.8	21.214	69	14.5%	4.50 [-2.39, 11.39]	
Yassin (2019) [12]	6.6	5.9	87	10.9	5.8	87	17.9%	-4.30 [-6.04, -2.56]	
Subtotal (95% CI)			251			251	49.7%	-1.48 [-5.23, 2.27]	
Heterogeneity: Tau ² =	7.62; C	hi² = 8.4	3, df =	2 (P = 0).01); l² =	76%			
Test for overall effect:	Z = 0.77	' (P = 0.4	44)						
Total (95% CI)			639			639	100.0%	2.59 [-3.22, 8.39]	
Heterogeneity: Tau ² =	48.36; 0	Chi ^z = 11	78.24,	df = 5 (F	< 0.000	01); I r =	97%		-20 -10 0 10 20
Test for overall effect:	Z = 0.87	' (P = 0.3	38)						-20 -10 0 10 20 Decreased IIEF Increased IIEF
Test for subarous diff.		Ohiz-	440 -	F 4 (D	- 0.043	2 - 75 (2 OV		Decreased HEF IIItreased HEF


Test for subgroup differences: $Chi^2 = 4.10$, df = 1 (P = 0.04), $I^2 = 75.6\%$

В



Test for subgroup differences: Chi² = 2.65, df = 1 (P = 0.10), l² = 62.3%







cholesterol, VLDL cholesterol, and fasting insulin reductions. Men with high cardiovascular risk should be counselled that the cardiovascular safety of testosterone therapy is uncertain [24]. Our meta-analysis decrease in DBP and slight increment in SBP. Nonetheless, a recent study revealed a slight decline in LDL levels and no influence on blood pressure [26]. Eleven studies reported a greater reduction in BMI following treatment, contradicting the proposed studies. Such as, a 2022 study by Michael Kreiberg et al. [27] reported slight increment in BMI indexes after testosterone therapy. Three studies found a correlation between serum total testosterone levels and AMS scores and IIEF scores. The administration of testosterone led to a significant reduction in AMS scores and an increase in IIEF scores. However, various other studies have found either no association or a weak association between this treatment and both scoring systems. Jae II Kang et al. [28] found that total serum testosterone had no strong association with the AMS total score or its three subsites (p > 0.05). Total serum testosterone demonstrated a weakly significant positive correlation (r = 0.124, p = 0.034) with IIEF total scores. In another study, A. Sansone et al. [29] discovered that dihydrotestosterone (DHT)

А

	Post-treatment		ent	Pre-t	reatm	ent		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.15.1 Testosterone									
Boyanov (2003) [19]	15.54	3.41	24	9.56	2.33	24	7.2%	5.98 [4.33, 7.63]	
Dhindsa (2015) [13]	19.4	9.7	20	9	2.9	20	5.7%	10.40 [5.96, 14.84]	
Groti (2018) [22]	17.04	3.07	28	7.24	1.97	28	7.3%	9.80 [8.45, 11.15]	
Groti (2020) [5]	23.5	4.81	28	7.24	1.97	28	7.1%	16.26 [14.33, 18.19]	•
Kapoor (2006) [18]	12.79	0.79	24	8.63	0.51	24	7.5%	4.16 [3.78, 4.54]	-
Khirpun (2018) [21]	15	6.4	40	9.6	2.7	40	7.0%	5.40 [3.25, 7.55]	
Yassin (2019) [12]	16.7	4.5	229	8.2	2.1	229	7.4%	8.50 [7.86, 9.14]	-
Subtotal (95% CI)			393			393	49.2%	8.54 [5.78, 11.31]	-
Heterogeneity: Tau ² =	12.88; C	hi² = 2!	92.06, 0	df = 6 (P	< 0.00	(001); P	²= 98%		
Test for overall effect:	Z = 6.05	(P < 0.1	00001)						
1.15.2 Placebo									
Boyanov (2003) [19]	11.2	3.16	24	10.76	3	24	7.2%	0.44 [-1.30, 2.18]	_
Dhindsa (2015) [13]	9.7	4.6	14	8.3	2.8	14	6.7%	1.40 [-1.42, 4.22]	-+
Groti (2018) [22]	9.83	1.51	27	7.96	1.34	27	7.4%	1.87 [1.11, 2.63]	
Groti (2020) [5]	17.47	2.7	27	7.96	1.34	27	7.3%	9.51 [8.37, 10.65]	
Kapoor (2006) [18]	8.39	0.58	24	8.63	0.51	24	7.5%	-0.24 [-0.55, 0.07]	-
Khirpun (2018) [21]	9.8	2.9	40	9.9	2.6	40	7.3%	-0.10 [-1.31, 1.11]	-+-
Yassin (2019) [12]	8.7	2.7	87	9.6	2.4	87	7.4%	-0.90 [-1.66, -0.14]	
Subtotal (95% CI)			243			243	50.8 %	1.71 [-0.54, 3.96]	
Heterogeneity: Tau ² = Test for overall effect:				′=6(P <	< 0.00C	i01); I²÷	= 98%		
Total (95% CI)			636			636	100.0%	5.08 [2.90, 7.26]	
Heterogeneity: Tau ² =	16.54; C	hi² = 10	303.58	df=13	(P < 0	.00001); I ² = 999	6 -	
Test for overall effect:					•				-10 -5 Ó 5 10 Decreased TT Increased TT
Test for subgroup diff	erences:	Chi r =	14.09,	df=1 (F	P = 0.0	002), I²	= 92.9%		Decreased in Increased II
В									
	Post-ti	eatme	nt	Pre-t	reatme	ent		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	IV, Random, 95% CI

	Post-t	reatme	ent	Pre-t	reatme	nt		Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl		
1.18.1 Testosterone											
Dhindsa (2015) [13]	478.86	142.2	20	156.5	45.11	20	15.1%	322.36 [256.98, 387.74]			
Hackett (2014) [14]	235.3	57	91	187.7	57	91	18.5%	47.60 [31.04, 64.16]	+		
Khirpun (2018) [21]	323	167	40	208	142	40	14.9%	115.00 [47.07, 182.93]			
Subtotal (95% CI)			151			151	48.5%	159.78 [-3.67, 323.24]			
Heterogeneity: Tau ² = 3	20082.22	; Chi ^z =	65.79,	df = 2 (P	< 0.000	01); I ≥ :	= 97%				
Test for overall effect: 2	Z = 1.92 (F	P = 0.08	i)								
1.18.2 Placebo											
Dhindsa (2015) [13]	177	59	14	145.74	41.6	14	17.4%	31.26 [-6.56, 69.08]			
Hackett (2014) [14]	181.2	63.6	95	181.2	63.6	95	18.5%	0.00 [-18.09, 18.09]	+		
Khirpun (2018) [21]	230	134	40	223	140	40	15.6%	7.00 [-53.06, 67.06]			
Subtotal (95% CI)			149			149	51.5%	6.73 [-10.57, 24.03]	•		
Heterogeneity: Tau ² = 3				! (P = 0.3	4); I² = €	i%					
Test for overall effect: 2	Z = 0.76 (F	P = 0.45	5)								
Total (95% CI)			300			300	100.0%	81.21 [23.87, 138.54]	•		
Heterogeneity: Tau ² = -	4546.92;	Chi ^z = 9	96.93, d	f=5(P <	0.0000	1); I² =	95%				
Test for overall effect: 2									-200 -100 Ó 100 200 Decreased FT Increased FT		
Test for subgroup diffe	rences: C	chi ² = 3.		Decleased FT Incleased FT							

Fig. 7. Effects on Hormonal levels; A = TT (Total testosterone), B = FT (Free testosterone), C = SBHG (sex hormone binding globulin), D = PSA (Prostate specific antigen).

concentrations in individuals with normal testosterone levels (n = 416, Total T > 12 nmol/L) were powerful determinants of AMS scores employing multivariate strategies. In men with biological hypogonadism (Total testosterone 12 nmol/L), total and free testosterone were correlated with AMS results rather than DHT. This relationship was not observed for IIEF scores. Two studies found a substantial decline in mortality versus placebo. In terms of hormones, the concentrations of total testosterone, free testosterone, SHBG, and PSA were investigated. Total and free testosterone levels increased substantially, whereas SHBG levels declined. However, no correlation was observed between this therapy and PSA levels.

Our meta-analysis has several benefits: (1) Due to the inclusion


of five additional studies, the sample size of our meta-analysis is more significant than that of previous meta-analyses, which lends credence to our findings. (2) The publication biases were calculated using various plots and tests, including the funnel plot, Egger's test, and Begg's test, revealing no publication bias. (3) Sensitivity analysis was used to determine how heterogeneous studies affected the pooled estimate. (4) Moreover, we compared our meta-analysis to previous meta-analyses conducted by Jianzhong Zhang et al. Which consisted of eight studies, all of which were RCTs. Our metaanalysis did include one observational study whose publication bias was assessed using the New Castle-Ottawa Scale. (5) Our study included some additional outcomes as a result of new data in the literature; these outcomes included mortality, total testosterone,

С

Mean 24 27.21 28.7 22.8	10 8.66 0.7	20 28	Mean 27 26.89	SD 14	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
27.21 28.7	8.66 0.7	28		14	20			
27.21 28.7	8.66 0.7	28		14	20			
28.7	0.7		26.90			9.1%	-3.00 [-10.54, 4.54]	
			20.00	10.86	28	12.8%	0.32 [-4.82, 5.46]	+
22.8		16	37.9	2.2	16	19.3%	-9.20 [-10.33, -8.07]	•
	20.2	40	20.8	20.7	40	7.4%	2.00 [-6.96, 10.96]	
		104			104	48.7%	-3.08 [-9.59, 3.43]	◆
.73; Chi	i ^z = 20.	08, df=	= 3 (P =	0.0002)	; I ² = 85	5%		
0.93 (F	^o = 0.35	5)						
27	13	14	26	13	14	6.8%	1.00 [-8.63, 10.63]	- <u>+</u> -
21.68	6.54	27	21.58	6.28	27	16.0%	0.10 [-3.32, 3.52]	*
30.8	1.3	16	39.7	2	16	19.3%	-8.90 [-10.07, -7.73]	•
21.2	16	40	18.5	17.6	40	9.3%	2.70 [-4.67, 10.07]	
		97			97	51.3%	-1.86 [-8.73, 5.02]	•
.43; Chi	i ^z = 34.	79, df =	=3(P <	0.0000	1); I z = 9	91%		
0.53 (F	° = 0.60	D)						
		204			204	400.0%	2241622 0441	
							-3.24 [-0.33, -0.14]	
			=7(P <	0.0000	1); $ ^2 = 8$	38%		-100 -50 0 50 10
`		·						Decreased SHBG Increased SHBG
	73; Ch 0.93 (F 27 21.68 30.8 21.2 43; Ch 0.53 (F 60; Ch 2.05 (F	22.8 20.2 73; Chi ² = 20. 0.93 (P = 0.3; 27 13 21.68 6.54 30.8 1.3 21.2 16 43; Chi ² = 34. 0.53 (P = 0.6; 60; Chi ² = 56. 2.05 (P = 0.9;	22.8 20.2 40 104 73; Chi ² = 20.08, df = 0.93 (P = 0.35) 27 13 14 21.68 6.54 27 30.8 1.3 16 21.2 16 40 97 43; Chi ² = 34.79, df = 0.53 (P = 0.60) 201 60; Chi ² = 56.10, df = 2.05 (P = 0.04)	22.8 20.2 40 20.8 104 73; Chi [#] = 20.08, df = 3 (P = 0.93 (P = 0.35) 27 13 14 26 21.68 6.54 27 21.58 30.8 1.3 16 39.7 21.2 16 40 18.5 97 43; Chi [#] = 34.79, df = 3 (P < 0.53 (P = 0.60) 201 60; Chi [#] = 56.10, df = 7 (P < 2.05 (P = 0.04)	22.8 20.2 40 20.8 20.7 104 73; Chi ² = 20.08, df = 3 (P = 0.0002) 0.93 (P = 0.35) 27 13 14 26 13 21.68 6.54 27 21.58 6.28 30.8 1.3 16 39.7 2 21.2 16 40 18.5 17.6 97 43; Chi ² = 34.79, df = 3 (P < 0.0000' 0.53 (P = 0.60) 201 60; Chi ² = 56.10, df = 7 (P < 0.0000' 2.05 (P = 0.04)	22.8 20.2 40 20.8 20.7 40 104 104 104 73; Chi ² = 20.08, df = 3 (P = 0.0002); P = 68 0.93 (P = 0.35) 27 13 14 26 13 14 21.68 6.54 27 21.58 6.28 27 30.8 1.3 16 39.7 2 16 21.2 16 40 18.5 17.6 40 97 97 97 97 97 43; Chi ² = 34.79, df = 3 (P < 0.00001); I ² = 5 0.60) 201 201 60; Chi ² = 56.10, df = 7 (P < 0.00001); I ² = 5 2.05 (P = 0.04) 20 20	22.8 20.2 40 20.8 20.7 40 7.4% 104 104 104 48.7% 73; Chi [#] = 20.08, df = 3 (P = 0.0002); I [#] = 85% 0.93 (P = 0.35) 27 13 14 26 13 14 6.8% 21.68 6.54 27 21.58 6.28 27 16.0% 30.8 1.3 16 39.7 2 16 19.3% 21.2 16 40 18.5 17.6 40 9.3% 97 97 51.3% 97 51.3% 43; Chi [#] = 34.79, df = 3 (P < 0.00001); I [#] = 91% 0.53 (P = 0.60) 201 201 100.0% 60; Chi [#] = 56.10, df = 7 (P < 0.00001); I [#] = 88% 2.05 (P = 0.04)	22.8 20.2 40 20.8 20.7 40 7.4% 2.00 [-6.96, 10.96] 104 104 48.7% -3.08 [-9.59, 3.43] 73; Chi ² = 20.08, df = 3 (P = 0.0002); P = 85% 0.93 (P = 0.35) 27 13 14 26 13 14 6.8% 1.00 [-8.63, 10.63] 21.68 6.54 27 21.58 6.28 27 16.0% 0.10 [-3.32, 3.52] 30.8 1.3 16 39.7 2 16 19.3% -8.90 [-10.07, -7.73] 21.2 16 40 18.5 17.6 40 9.3% 2.70 [-4.67, 10.07] 97 97 51.3% -1.86 [-8.73, 5.02] 43; Chi ² = 34.79, df = 3 (P < 0.00001); I ² = 91% 0.53 (P = 0.60) 201 201 100.0% -3.24 [-6.33, -0.14] 60; Chi ² = 56.10, df = 7 (P < 0.00001); I ² = 88%

Test for subgroup differences: Chi² = 0.06, df = 1 (P = 0.80), l² = 0%

D





free testosterone, SHBG, and PSA.

Even though this analysis produced adequate statistical evidence, some limitations should be highlighted. (1) First, variations in study designs, interventions, patient characteristics such as body mass index, age, sample sizes, and ethnicity, and discrepancies in trial characteristics may have contributed to clinical heterogeneity. (2) Second, the follow-up periods for most studies varied, with some studies reporting longer periods. Long-term follow-ups are more useful when evaluating hormonal diseases like hypogonadism in order to control the body's homeostasis. (3) Numerous studies used different doses of testosterone at different weeks, and the mode of administration of testosterone varied among included studies. Additionally, majority of studies did not include doses of control groups, which could create some uncertainty. (4) Only two or three randomized controlled trials examined body fat, AMS and IIEF scores, free testosterone, and mortality rates. (5) All included RCTs except Groti 2020 [5] had selective reporting bias. More trials were required to investigate the effect of testosterone therapy on sexual function.

5. Conclusion

According to our meta-analysis, testosterone therapy can improve glycemic control, reduce total cholesterol, HDL levels, and triglycerides, as well as decrease BMI and waist circumference in hypogonadal T2DM patients. In these patients, we recommend this therapy in addition to anti-diabetic therapy. In addition, additional standard quality RCTs are required to investigate the additional effects of Testosterone therapy in hypogonadal men with T2DM.

Disclosures

The authors report no proprietary or commercial interest in any product mentioned or concept discussed in the article.

Author's contributions

Satesh Kumar: Protocol development, Data collection, Data analysis, Manuscript writing.Mahima Khatri: Protocol development, Data collection, Data analysis, Manuscript writing.Rahat Ahmed Memon: Data collection, Data analysis, Manuscript writing.Jordam Llerena Velastegui: Data collection, Manuscript writing.Kristina Zumbana Podaneva: Manuscript writing.Daniela Benitez Gutierrez: Protocol development, Data collection.Bilawal Nadeem: Protocol development.Akhil Raj Anumolu: Protocol development, Manuscript writing.Masood Azhar: Data analysis, Manuscript editing.Ahmad Zain: Data analysis, Manuscript editing.

Declaration of competing interest

None.

Acknowledgements

None.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.dsx.2022.102588.

References

- [1] Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an endocrine society clinical Practice guideline. J Clin Endocrinol Metab 2018 May 1;103(5):1715–44. https://doi.org/10.1210/ jc.2018-00229. PMID: 29562364.
- [2] Fernández-Miró M, Chillarón JJ, Pedro-Botet J. Déficit de testosterona, síndrome metabólico y diabetes mellitus [Testosterone deficiency, metabolic syndrome and diabetes mellitus]. Spanish Med Clin 2016 Jan 15;146(2): 69–73. https://doi.org/10.1016/j.medcli.2015.06.020. Epub 2015 Oct 1. PMID: 26433309.
- [3] Caliber M, Saad F. Testosterone therapy for prevention and reversal of type 2 diabetes in men with low testosterone. Curr Opin Pharmacol 2021 Jun;58: 83–9. https://doi.org/10.1016/j.coph.2021.04.002. Epub 2021 May 13. PMID: 33993064.
- [4] Jenkins CR, Rittel A, Sturdivant RX, Wan J, Clerc PG, Manning E, Jenkins LM, Wardian JL, Graybill SD. Glycemic benefits with adherence to testosterone therapy in men with hypogonadism and type 2 diabetes mellitus. Andrology 2021 Jul;9(4):1076–85. https://doi.org/10.1111/andr.12990. Epub 2021 Mar 8. PMID: 33606360.
- [5] Groti Antonič K, Antonič B, Žuran I, Pfeifer M. Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial). Aging Male 2020 Dec;23(5):1442–54. https://doi.org/10.1080/ 13685538.2020.1793132. Epub 2020 Aug 26. PMID: 32844712.
- [6] Zhang J, Yang B, Xiao W, Li X, Li H. Effects of testosterone supplement treatment in hypogonadal adult males with T2DM: a meta-analysis and systematic review. World J Urol 2018 Aug;36(8):1315–26. https://doi.org/10.1007/ s00345-018-2256-0. Epub 2018 Mar 6. PMID: 29511802.
- [7] Gianatti EJ, Dupuis P, Hoermann R, Zajac JD, Grossmann M. Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab 2014 Oct;99(10):3821-8. https://doi.org/10.1210/jc.2014-1872. Epub 2014 Jun 30. PMID: 24978674.
- [8] Gianatti EJ, Dupuis P, Hoermann R, Strauss BJ, Wentworth JM, Zajac JD, Grossmann M. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. Diabetes Care 2014 Aug;37(8):2098–107. https://doi.org/10.2337/dc13-2845. Epub 2014 May 7. PMID: 24804695.
- [9] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009 Jul 21;339:

b2700. https://doi.org/10.1136/bmj.b2700. PMID: 19622552; PMCID: PMC2714672.

- [10] Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. Cochrane bias methods group; Cochrane statistical methods group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011 Oct 18;343:d5928. https://doi.org/ 10.1136/bmj.d5928. PMID: 22008217; PMCID: PMCIJ96245.
- [11] Wells GA, Tugwell P, O'Connell D, et al. The newcastle-ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2015. Retrieved from. [Google Scholar] [Ref list], http://www.ohri.ca/programs/ clinical_epidemiology/oxford.asp.
- [12] Yassin A, Haider A, Haider KS, Caliber M, Doros G, Saad F, Garvey WT. Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: eight-year data from a registry study. Diabetes Care 2019 Jun;42(6):1104–11. https://doi.org/10.2337/dc18-2388. Epub 2019 Mar 12. PMID: 30862651.
- [13] Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, Green K, Makdissi A, Hejna J, Chaudhuri A, Punyanitya M, Dandona P. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care 2016 Jan;39(1):82–91. https://doi.org/10.2337/dc15-1518. Epub 2015 Nov 29. PMID: 26622051; PMCID: PMC4686848.
- [14] Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, BLAST Study Group. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med 2014 Mar;11(3):840–56. https:// doi.org/10.1111/jsm.12404.Epub.2013.Dec.6. PMID: 24308723.
- [15] Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD, Channer KS. TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011 Apr;34(4): 828–37. https://doi.org/10.2337/dc10-1233. Epub 2011 Mar 8. PMID: 21386088; PMCID: PMC3064036.
- [16] Gopal RA, Bothra N, Acharya SV, Ganesh HK, Bandgar TR, Menon PS, Shah NS. Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus. Endocr Pract 2010 Jul-Aug;16(4):570–6. 10.4158/EP09355.OR. PMID: 20150021.
- [17] Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009 Nov-Dec;30(6): 726–33. https://doi.org/10.2164/jandrol.108.007005. Epub 2009 Jul 3. PMID: 19578132.
- [18] Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006 Jun;154(6):899–906. https://doi.org/10.1530/eje.1.02166. PMID: 16728551.
- [19] Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003 Mar;6(1):1–7. PMID: 12809074.
- [20] Hackett G, Cole N, Mulay A, Strange RC, Ramachandran S. Long-term testosterone therapy in type 2 diabetes is associated with reduced mortality without improvement in conventional cardiovascular risk factors. BJU Int 2019 Mar;123(3):519–29. https://doi.org/10.1111/bju.14536. Epub 2018 Oct 16. PMID: 30216622.
- [21] Khripun I, Vorobyev S, Belousov I, Kogan M, Zitzmann M. Influence of testosterone substitution on glycemic control and endothelial markers in men with newly diagnosed functional hypogonadism and type 2 diabetes mellitus: a randomized controlled trial. Aging Male 2019 Dec;22(4):241–9. https:// doi.org/10.1080/13685538.2018.1506918. Epub 2018 Sep 20. PMID: 30235049.
- [22] Groti K, Žuran I, Antonič B, Foršnarič L, Pfeifer M. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male 2018 Sep;21(3):158–69. https://doi.org/10.1080/ 13685538.2018.1468429. Epub 2018 Apr 30. PMID: 29708829.
- [23] Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. quiz 655 J Sex Med 2011 Mar;8(3):639–54. https://doi.org/10.1111/ j.1743-6109.2010.02200.x. PMID: 21711483.
- [24] Jayasena CN, Anderson RA, Llahana S, Barth JH, MacKenzie F, Wilkes S, Smith N, Sooriakumaran P, Minhas S, Wu FCW, Tomlinson J, Quinton R. Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clin Endocrinol 2022 Feb;96(2):200–19. https://doi.org/ 10.1111/cen.14633. Epub 2021 Nov 22. PMID: 34811785.
- [25] Dandona P, Dhindsa S, Ghanim H, Saad F. Mechanisms underlying the metabolic actions of testosterone in humans: a narrative review. Diabetes Obes Metabol 2021 Jan;23(1):18–28. https://doi.org/10.1111/dom.14206. Epub 2020 Oct 19. PMID: 32991053.
- [26] Mangolim AS, Brito LAR, Nunes-Nogueira VDS. Effectiveness of testosterone replacement in men with obesity: a systematic review and meta-analysis. Eur J Endocrinol 2021 Dec 3;186(1):123–35. https://doi.org/10.1530/EJE-21-0473. PMID: 34738915.
- [27] Bandak M, Jørgensen N, Juul A, Lauritsen J, Kreiberg M, Oturai PS, Helge JW, Daugaard G. A randomized double-blind study of testosterone replacement

Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16 (2022) 102588

therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention). BMC Cancer 2017 Jul 3;17(1):461. https://doi.org/10.1186/s12885-017-3456-5. PMID: 28673265; PMCID: PMC5494856.

[28] Kang 2nd J, Ham BK, Oh MM, Kim JJ, Moon du G. Correlation between serum total testosterone and the AMS and IIEF questionnaires in patients with erectile dysfunction with testosterone deficiency syndrome. Korean J Urol 2011 Jun;52(6):416–20. https://doi.org/10.4111/kju.2011.52.6.416. Epub 2011 Jun 17. PMID: 21750754; PMCID: PMC3123819.

[29] Sansone A, Kliesch S, Dugas M, Sandhowe-Klaverkamp R, Isidori AM, Schlatt S, Zitzmann M. Serum concentrations of dihydrotestosterone are associated with symptoms of hypogonadism in biochemically eugonadal men. J Endocrinol Invest 2021 Nov;44(11):2465–74. https://doi.org/10.1007/ s40618-021-01561-0. Epub 2021 Apr 3. PMID: 33811609; PMCID: PMC8502125.